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Executive Summary 
Background: Scientific and medical progress in oncology has led to the in-
troduction of new medicines in rapid succession. In addition, the develop-
ment of new therapy modalities, the so-called "targeted therapies” such as 
e.g. monoclonal antibodies or tyrosinekinase-inhibitors ("small molecules"), 
has resulted in swift increases in medicine costs in oncology in hospitals. 
The fast and, to some extent, uncontrolled implementation of these expen-
sive cancer medicines has affected hospital drug budgets. 
The development of a Horizon Scanning System (HSS) which aims at identi-
fying and evaluating new drug therapies in oncology early on, i.e. before 
their routine introduction for cancer treatment, could prepare Austrian hos-
pitals (hospital administrators and drug commissions respectively) for new 
anticancer medicines, and could contribute to making rational decisions and 
planning prospective budgets. 
The main components of such a Horizon Scanning System are the determi-
nation of relevant information sources for the systematic identification of 
emerging anticancer drugs, the establishment of a useful filtering and pri-
oritisation instrument, the set up of a network of Austrian oncologists in-
volved in the Horizon Scanning process and the definition of the parameters 
and the format of early assessment. 
Objectives: This project was performed in order to develop a concept for the 
preparation of a HSS for anticancer drugs in Austria and to test the two im-
portant steps of identification and priority setting within a first feasibility 
study. 
Methods: A literature and internet search based on the EUnetHTA WP7 
HSS-review (overview of Horizon Scanning activities) was performed to 
identify existing Horizon Scanning Systems and relevant information 
sources for new anticancer drugs. Experts from established HSSs, mainly 
members of EuroScan, were contacted for information about their identifica-
tion and prioritisation processes. Existing methods were then adapted to the 
needs of Horizon Scanning in oncology.  Clinical experts were involved in 
the priority-setting process and the selection of new anticancer drugs for 
performing an early assessment. In a pilot run, we tested the feasibility of 
the concept. 
Results: In a time period of three months about sixty selected information 
sources for oncology were scanned weekly to identify emerging anticancer 
drugs or drugs with an extension of indication in phase II/ III of clinical 
testing. Our scanning revealed 116 different anticancer drugs for which we 
extracted relevant data. Three clinical experts in oncology then independ-
ently applied seven prioritisation criteria with an underlying score to the po-
tentially important anticancer drugs. We analysed their preliminary estima-
tions by calculating a mean score. The number of anticancer drugs relevant 
to the Austrian health care system could thereby be reduced to five, al-
though this result has to be interpreted carefully. Prioritisations by the ex-
perts clearly differed. Therefore, a final decision about which anticancer 
drugs should undergo early assessment was not feasible after calculating a 
mean score. Instead, a multistage prioritisation process must be used to 
reach a consensus between oncologists. In addition, our experts have com-
mented on the proposed procedures of drug identification and prioritisation. 
medical progress in 
oncology affects 
hospital drug budgets 
Horizon Scanning for 
anticancer drugs to 
inform decision makers 
development of a 
concept for a Horizon 
scanning system in 
oncology 
 methods include 
literature search, 
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methods 
feasibility study showed 
the need for slight 
changes in the 
identification and 
prioritisation process 
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Their suggestions mainly dealt with how drugs are identified (i.e. more re-
stricted inclusion criteria) and who makes up the expert panel (more experts 
with expertise in specific tumour entities). Their input could now be used to 
optimize the Horizon Scanning System and serve as a basis for further dis-
cussions.  
Conclusions: The establishment of a Horizon Scanning System for antican-
cer drugs is an important tool to prepare Austrian hospitals for new/ emerg-
ing medicines. In principle our first experiences with the Horizon Scanning 
System from the feasibility study were acceptable but several changes, espe-
cially regarding the collection of data on anticancer drugs and the priority 
setting process, were proposed by our experts. The next steps will be to work 
out an optimized, final concept with various stakeholders (e.g. hospital ad-
ministrators, clinical experts, drug commissions) in consideration of the re-
sults of the feasibility study. Secondly, the Horizon Scanning System should 
be made standard practice to regularly provide Austrian hospitals (hospital 
management and drug commissions) with information about new/ emerging 
anticancer drugs to support their financial drug budget planning and ra-
tional decision making. Third, as an input for the international HTA-
community, the Ludwig Boltzmann Institute for HTA will join EuroScan in 
2008/ 2009. 
 
consideration of weak 
points to improve the 
existing concept and 
make HSS standard 
practice 
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Zusammenfassung 
Einleitung: Der wissenschaftliche und medizinische Fortschritt in der On-
kologie führt in rascher Abfolge zur Einführung neuer Medikamente. Mit 
der Entwicklung neuer Therapiemodalitäten, den so genannten „targeted 
therapies“ wie z.B. monoklonale Antikörper oder Tyrosinkinasehemmer 
(„small molecules“), ist es in den Krankenhäusern zu einer rasanten Steige-
rung der Medikamentenkosten in der Onkologie gekommen. Die schnelle, 
teils unkontrollierte Implementierung dieser teuren Krebsmedikamente in 
die klinische Praxis hat Auswirkungen auf die Arzneimittelbudgets der Ös-
terreichischen Krankenhäuser. 
Zielsetzung: Der Aufbau eines  „Horizon-Scanning-Systems“ zur Früher-
kennung und Bewertung von neuen medikamentösen Therapiekonzepten in 
der Onkologie, d.h. bevor einer routinemäßigen Einführung in die Patien-
tenbehandlung, soll Krankenanstalten (resp. Arzneimittelkommissionen) 
auf neue Krebsmedikamente gezielt vorbereiten, zur rationalen Entschei-
dungsfindung beitragen sowie die prospektiven Budgetplanung unterstützen 
und einen wissenschaftlich begründeten Einsatz von Krebsmedikamenten 
sicherstellen. 
Horizon Scanning Systeme umfassen die folgenden sequentiellen Schritte: 
die Identifikation von geeigneten Informationsquellen für das Herausfiltern 
neuer Krebsmedikamente, die Festlegung eines geeigneten Priorisierungs-
Instrumentes, die Zusammenstellung eines Expertenteams und die Erarbei-
tung des Formats und der Methode für die Durchführung von frühen As-
sessments. Das Ziel dieses Projektes war die Entwicklung eines Konzeptes 
für ein Horizon Scanning System (HSS) in der Onkologie sowie die Prüfung 
der Machbarkeit der Schritte „Identifikation“ und „Priorisierung“ im Rah-
men einer Studie. 
Methode: Ausgehend von EUnetHTA WP7 Horizon Scanning Bericht wurde 
eine Literatursuche durchgeführt, um bestehende HSS-Aktivitäten und ge-
eignete Informationsquellen für den onkologischen Bereich zu identifizie-
ren. Zusätzlich wurden Experten zu Informationsquellen und deren Priori-
sierungsprozessen befragt. Es konnten bestehende Methoden übernommen 
bzw. an ein HSS speziell für die Onkologie angepasst werden. Die Durch-
führbarkeit des HSS wurde in Zusammenarbeit mit klinischen Experten ge-
testet. 
Ergebnis: In einem Zeitraum von 3 Monaten wurden über 60 verschieden 
Informationsquellen einmal pro Woche gescannt und dabei Informationen 
zu neuen Krebsmedikamenten in der Entwicklung extrahiert.  Es wurden 
116 verschiedene Arzneistoffe identifiziert, welche anschließend von 3 un-
abhängigen klinischen Experten mittels 7 definierten Kriterien priorisiert 
wurden. Die drei Einschätzungen wurden anhand einer hinterlegten Punk-
tezahl quantifiziert und dann ein durchschnittlicher Punktewert pro Arznei-
stoff ermittelt. Dadurch konnte die Anzahl der für das Österreichische Ge-
sundheitssystem relevanten Arzneistoffe auf 5 eingeschränkt werden, wobei 
dieses Ergebnis durch die z.T. großen Unterschiede in der Einschätzung 
durch die Experten, nur beschränkt aussagekräftig ist. Eine endgültige Fest-
legung, welche Arzneistoffe nun einem frühen Assessment zugeführt werden 
sollen, muss demnach durch einen mehrstufigen Konsensfindungsprozess 
erreicht werden. Das Expertenteam wurde zur Machbarkeit des vorgeschla-
genen HSS befragt und es zeigten sich notwendige Änderungen in den Ein-
Fortschritt in der 
Krebstherapie wirkt sich 
auf Arzneimittelbudgets 
der Krankenha¨user aus 
Entwicklung eines 
Konzeptes fu¨r ein 
Horizon Scanning 
System in der Onkologie  
Literatursuche und 
Expertenkontakt  
machbares Konzept aber 
Optimierung bei 
Identifikation und 
Priorisierungsprozess 
notwendig 
Horizon Scanning in Oncology 
10 LBI-HTA | 2008 
schlusskriterien bei der Identifikation von Krebsmedikamenten sowie in der 
Zusammensetzung des Expertenteams. 
Schlussfolgerung: Der Aufbau und die Einführung eines Horizon Scanning 
Systems für den Bereich der Onkologie ist ein wichtiger Beitrag zur Vorbe-
reitung von Krankenhäusern auf  neue Medikamente in der Krebstherapie.  
Die erste Testung des Konzeptes verlief gut, allerdings wurden Änderungen 
zur Verbesserung des HSS von den Experten vorgeschlagen. Die nächsten 
Schritte umfassen deshalb die Ausarbeitung eines optimierten Konzeptes 
unter Einbeziehung verschiedener Entscheidungsträger (z.B. Krankenhaus-
verwaltungen, Arzneimittelkommissionen, Ärzte) sowie die nachfolgende 
Implementierung des HSS in die Praxis. Als internationalen Beitrag auf 
dem Gebiet Health Technology Assessment bzw. Horizon Scanning wird das 
Ludwig Boltzmann Institut für HTA noch im Jahre 2008 EuroScan beitre-
ten. 
 
Diskussion des HSS-
Konzeptes mit 
Entscheidungstra¨gern 
und Implementierung in 
die Praxis 
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1 Introduction 
1.1 Background 
Around 35,000 people are diagnosed with cancer each year in Austria and af-
ter cardiovascular diseases, malignant cancer is the second most common 
cause of death in both sexes [1]. These facts illustrate that cancer is one of 
the major health problems Austria, as many other countries, has to face. 
Over the past years basic and clinical research in oncology has been steadily 
increasing and is still expanding. Scientific and medical progress in this 
field has led in rapid succession to the introduction of many new medicines 
and the development of new therapy modalities, the so-called "targeted 
therapies” (e.g. monoclonal antibodies, tyrosinekinase-inhibitors). Accord-
ing to the annual report of the European Medicines Agency (EMEA) from 
the year 2007, cancer treatment was the most-represented therapeutic area 
for which positive orphan-designation opinions were adopted (55% of 
COMP/ Committee for Orphan Medicinal Products opinions), for which the 
highest proportion of initial marketing-authorisation applications was re-
ceived (26% of applications for new products) and for which the highest 
number of positive CHMP/ Committee for Medicinal Products for Human 
Use opinions were adopted (28% of positive opinions)[2]. However, there are 
large differences between countries with regard to the level of uptake and 
the time period over which cancer drugs become available to patients. Aus-
tria was one of the three countries which have been shown to be leaders in 
terms of adoption and availability of new cancer drugs [3]. 
The variety of new anticancer drugs available for therapy not only offers im-
proved cancer treatments but also brings about means new challenges. On 
the one hand, clinicians have to have an overview of medical progress and 
choose the best suitable therapy regime for each patient. On the other hand, 
the health system (i.e. hospitals) has to deal with increasing expenditures 
because cancer therapy is one of the major cost drivers of medicine costs in 
Austrian hospitals [4]. The fast and, to some extent, uncontrolled implemen-
tation of these mostly expensive cancer medicines into clinical practice has 
already dramatically affected hospital drug budgets. 
1.2 Horizon Scanning Systems 
1.2.1 Introduction 
New health technologies (e.g., drugs) raise a lot of questions concerning 
managed introduction, financial burdens, organisational requirements, and 
clinical practice changes. They also require consideration of social or ethical 
aspects as well as their effect on health care systems. Some countries (e.g. 
UK, Norway, Sweden, Belgium, Canada, and Australia) have established so 
called Horizon Scanning Systems (HSS), Early Warning Systems or Alert 
Systems to support decision makers with early information about new health 
technologies prior to their adoption and introduction into the national 
health system [5]. 
cancer is one of the 
major health problems 
new therapy modalities 
in oncology 
increasing expenses for 
cancer therapy effect on 
hospitals’ drug budget 
support decision makers 
with information about 
new/ emerging health 
technologies 
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Since 1999 these HSS have been collaborating in an information network 
called EuroScan, which is hosted by the National Horizon Scanning Centre 
(NHSC), the British HSS [6, 7]. The long-term aim of EuroScan is to estab-
lish a permanent network among agencies and organisations in the field of 
HTA to evaluate and exchange information on new and changing technolo-
gies, to develop the sources of information used, to share applied methods 
for early assessment, and to disseminate information on early identification 
and assessment activities [8]. 
According to EuroScan, HSS focuses on health technologies that are new (in 
the phase of adoption, i.e. in the launch or early post-marketing stages) or 
emerging (pharmaceuticals in phase II or phase III clinical trials) or that 
represent a change in indication of an existing technology, or that are part of 
a group of developing technologies that, as a whole, may have an impact. 
Such a HSS consists of 5 sequenced main components and work steps: 
b Identification of technologies that have the potential to make a large 
impact on health and/ or health services 
b Prioritisation i.e. to filter and prioritise these technologies to select 
those most likely to have a significant future impact 
b Early assessment of likely impact in terms of health, service and fi-
nancial impact 
b Dissemination of the resulting information to relevant decision-
makers 
b Monitoring of assessed technologies. 
 
Most HSS units are part of a HTA agency and HSS can be seen as the first 
stage of a comprehensive HTA process [6]. The main difference is that HSSs 
focus on technologies early in the life cycle (identifying and assessing tech-
nologies that potentially might have an impact on the health care system), 
whereas HTA in general primarily focus on assessing established health 
technologies.  
1.2.2 Horizon Scanning in Oncology 
Due to the increasing interest in emerging and new health technologies rele-
vant to the Austrian health care system, in particular in the clinical field of 
oncology, interest was expressed to establish a Horizon Scanning System in 
oncology as part of the research program in the Austrian Ludwig Boltzmann 
Institute of Health Technology Assessment (LBI-HTA). 
We decided to establish a separate Austrian Horizon Scanning System in 
oncology only because most of the institutions collaborating within Euro-
Scan operate at a national level (e.g. differences in priority setting between 
health care systems), with additional awareness to the internationality of 
Horizon Scanning and secondly, oncology is one of the major fields of medi-
cal research with the lead in many (highly-expensive) new/ emerging drugs. 
Hence a HSS with a special focus on anticancer drugs is of great national 
and international importance and relevance.  
 
international network 
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components of a HSS 
HSS as part of HTA 
agencies 
establishment of a HSS 
for the identification of 
new/ emerging 
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Therefore, the development of a national Horizon Scanning System for the 
early identification and evaluation of new drug therapies in oncology, i.e. 
prior to routine introduction to cancer treatment should purposefully pre-
pare decision-makers in hospitals (hospital administration, drug commis-
sions, oncologists) for new cancer medicines with potential impact (clinical, 
economic) and should contribute to making rational decisions as well as 
planning prospective budgets. After the successful establishment of the HSS 
by the LBI-HTA in Austria, the institute will make an important contribu-
tion to the international HTA-community through joining the EuroScan 
Network. In exchange, the Network will grant access to the EuroScan data-
base in other fields of medicine as well. 
1.3 Objectives 
The aim of this project, which was carried out between July 2007 and May 
2008, was to develop a concept for setting up a Horizon Scanning System in 
Austria which places special emphasis on anticancer drugs.  The methods 
and knowledge from existing HSS should be used and adapted to the chal-
lenges in oncology. 
The project focussed on the following: 
b The identification of information sources which provide timely in-
formation on new/ emerging anticancer drugs, 
b The identification and presentation of the most important parameters 
on which information should be extracted from the identified sources, 
b The selection of relevant and useful criteria for the prioritisation 
process,  
b The establishment of a group of clinical experts in oncology who sup-
port and perform the selection/ prioritisation of  anticancer drugs 
with potential impact (e.g., clinical, economic) on the Austrian health 
care system, 
b The testing of the two major steps involved in the HSS (identification 
and prioritisation) within a short pilot feasibility study, 
b The preparation of a basis for discussion with stakeholders about the 
concrete implementation of the HSS into practice. 
 
target groups: decision-
makers in hospitals 
(hospital 
administration,  
drug commissions, 
oncologists) 
development of a 
concept for a HSS in 
oncology and the 
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2 Methods 
Search of the literature, contact to experts and a feasibility study to explore 
two important steps in the process of HSS (identification of health technolo-
gies and priority setting for early assessment) were used as methods within 
this project. 
2.1 Definition of Drugs to be identified by the 
HSS 
The first step was to determine an exact definition of the drugs which 
should be identified by systematically scanning several sources within the 
framework of our HSS: 
b Drugs that are designed for cancer therapy in adults concerning solid 
malignancies as well as leukaemia and lymphoma , 
b Anticancer drugs that are new (in the phase of adoption, i.e. in the 
launch or early post-marketing stages) or emerging (in phase II or 
phase III of clinical testing), 
b Approved anticancer drugs that represent a change in indication (ex-
tension of indication), 
b Anticancer drugs which will be in clinical use in Austria within a time 
period of 0 to 4 years, 
b Excluded are drugs used for only supportive therapy like antiemetics, 
bisphosponates etc. , 
b Excluded are other anticancer treatments other than drugs. 
2.2 Constitution of an Expert Panel 
Clinical oncologists are important for our HSS because they represent the 
expert panel that is responsible for the prioritisation of identified anticancer 
drugs. In our pilot study, we started with three well-reputed experts in on-
cology recommended by medical directors from three different Austrian 
hospitals which work closely with the LBI-HTA. They have graciously vol-
unteered to participate in the pilot process of developing a concept for an 
Austrian HSS in oncology: 
Prim. Univ. Doz. Dr. Peter Krippl, Department of Internal Medicine– Cen-
tre for Oncology and Haematology, LKH Fürstenfeld,  
Dr. Clemens Leitgeb, 1. Medical Department – Centre for Oncology and 
Haematology, Wilhelminenspital Vienna and  
Dr. Wolfgang Willenbacher, Department of Internal Medicine – Centre for 
Oncology and Haematology, University Hospital Innsbruck. 
 
literature search and 
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2.3 Identification of Information Sources which 
provide timely Information on new/ 
emerging Anticancer Drugs 
2.3.1 Searching for information sources 
Due to limited financial resources for this initial study, we included only in-
formation sources that are easily and freely accessible on the internet. We 
began by scanning internet sites already familiar to us, such as the American 
Society of Clinical Oncology homepage. From there we explored other use-
ful sources (i.e. including predominantly and reliable oncology-related in-
formation) for identifying new/ emerging anticancer drugs. Moreover, we 
searched for information sources used within the identification process of 
other Horizon Scanning- / Early Warning Systems by reading publications 
cited in the EUnetHTA WP7 Project Report (overview of horizon scanning 
activities [6]) and hand-searching their reference lists for further literature 
on this topic. In addition, based on recommendations of clinical oncologists 
regarding sources which they use to stay informed about state-of-the-art sci-
ence, various internet sites were included.  
We collected and tabulated all potential information sources (see chapter 
2.3.2) that provide predominately information about anticancer drugs.  In a 
feedback process we contacted four experts well known to the LBI-HTA 
from established HSSs to comment on our list of sources, to report their ex-
periences with the mentioned sources and to suggest additional ones. 
The following experts from HSSs provided us with their support and advice: 
Karla Douw, PhD, Centre for Applied Health Services Research and tech-
nology Assessment (CAST) at the University of Southern Denmark 
Anne Lee, MPhil, MRPharmS, Horizon Scanning, Scottish Medicines Con-
sortium (SMC), Scotland 
Dr. Sue Simpson, National Horizon Scanning Centre (NHSC) at the Uni-
versity of Birmingham, UK 
Leigh-Ann Topfer, Emerging Health Technologies, Canadian Agency for 
Drugs and Technologies in Health (CADTH), Canada 
2.3.2 Selection criteria for information sources 
Due to the fact that we used information sources mainly available to the 
public on the internet, we used the following criteria to judge a site as suit-
able for our scanning process [9].  
b Timeliness of information (periodical updates) 
b Quality of information provided (objectivity, transparency of primary 
source and credibility) 
b Accessibility (available free or with free subscription) 
b Oncology-related content 
b Usability (easy to scan, not too time consuming, electronic alerts or 
newsletters available) 
b Geographic coverage (international or national coverage) 
identification of 
information sources for 
oncology by literature 
search 
defined criteria for 
information sources on 
the Internet 
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Information sources were included in our list of internet sites if all the crite-
ria were fulfilled.  
2.4 Data Extraction 
After completing the selection of internet sources we generated an Excel 
spreadsheet that included a set of parameters for extracting relevant infor-
mation on new/ emerging anticancer drugs during the scanning process. The 
preparation and format of the available information on anticancer drugs is 
an essential step within the HSS, because the expert panel (see chapter 2.2) 
has to appraise the identified anticancer drugs on the basis of the provided 
information by applying defined criteria. The more comprehensive the in-
formation, the easier it is to do the priority setting process. We listed a set of 
parameters which we regarded as being important, and discussed our pro-
posal face to face with the experts.  
2.5 Definition of Criteria for Priority Setting 
Existing HSS, i.e. EuroScan, have already defined and established priority 
setting criteria [8]. We collected comprehensively the criteria that were de-
scribed in literature [10-13] and by EuroScan and assigned them to our pre-
defined categories. The definition of our final priority setting instrument 
comprising a useful and manageable set of criteria was reached in agreement 
with the expert panel and was tested in the context of the feasibility study. 
2.6 Feasibility Study 
Before a final implementation of a new Horizon Scanning System to support 
administrative and medical decision-making, the theoretical concept must 
be tested in the context of a feasibility study [13].  Therefore, in a pilot study 
between January and March 2008 we regularly scanned the predefined in-
formation sources and collected data about anticancer drugs. According to 
the selected parameters we tabulated the recorded information in an Excel 
spreadsheet and asked our expert panel to apply the prioritisation criteria to 
the identified anticancer drugs. The task was to narrow the topic list to a 
manageable number of anticancer drugs which could be further evaluated in 
the context of an early assessment. Moreover, the study was performed to 
answer the following questions: 
b Are the specified information sources suitable for an HSS in oncology 
(i.e. manageable and not too time consuming)? 
b What is the optimal scanning frequency (e.g. daily, weekly or 
monthly) and how much time is needed to scan the sources and ex-
tract data? 
b Are the extracted data detailed enough (is enough information pro-
vided) to apply the priority setting criteria? 
format for data 
extraction: Excel 
spreadsheet 
use of established 
criteria and adaptation 
to our needs 
testing of the 
identification and 
prioritisation process 
and answering questions 
regarding its feasibility 
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b Are the prioritisation criteria and the underlying score appropriate to 
reduce the initially large amount of identified anticancer drugs to a 
manageable number of substances? 
b How much time does it take to do the prioritisation? 
b What is the optimal size of an expert panel? Can three experts cover 
the wide field of oncology? 
b Which changes are necessary to optimize the HSS? 
b  What are the next important steps to make the HSS standard practice 
and to support decision makers with relevant information about rele-
vant anticancer drugs? 
2.7 Early Assessment of Anticancer Drugs 
Early assessments of relevant new/ emerging anticancer drugs are the main 
output of this and other HSS to support decision makers. Information on the 
format and methods of different agencies with existing HSS was collected 
from websites and published literature and was used to propose a prelimi-
nary concept for this next step of the HSS, which has yet to be conducted. 
 
early assessment as 
main output of a HSS 
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3 Results 
3.1 Information Sources 
3.1.1 General Classification 
The identified information sources based on the recommendations of ex-
perts and on published reports [9, 14-19] were summarized. To obtain a use-
ful combination of sources and to be comprehensive enough, we finally in-
cluded 63 different information sources available on the internet, which can 
be divided into 7 main categories (Figure 3.1-1). 
Figure 3.1-1: Main categories of information sources 
3.1.2 Regulatory Authorities 
FDA – U.S. Food and Drug Administration 
The U.S. Food and Drug Administration (FDA) is an agency within the De-
partment of Health and Human Services and is responsible for protecting 
the public health by assuring the safety, efficacy, and security of human and 
veterinary drugs, biological products, medical devices, nation’s food supply, 
cosmetics, and products that emit radiation. The FDA is also responsible for 
advancing the public health by helping to speed innovations that make 
medicines and foods more effective, safer, and more affordable; and helping 
the public get the accurate, science-based information they need to use 
medicines and foods to improve their health [20]. Concerning drugs, FDA 
regulates product approvals, OTC and prescription drug labelling and drug 
manufacturing standards. Especially the Centre for Drug Evaluation and 
Research (CDER) and the Office of Oncology Drug Products (OODP) which 
oversees development, approval, and regulation of drug treatments for can-
cer provide a lot of useful information on drugs on their homepages. See Ta-
ble 3.1-1 for a detailed description of FDA’s information sources regarding 
anticancer drugs. 
63 different information 
sources from 7 
categories 
FDA homepage provides 
information about drug 
approvals in the USA 
• Regulatory Authorities 
• Societies of Clinical Oncology (incl. Conference Abstracts) 
• Clinical Trial Registries 
• HTA Agencies with existing HSS 
• Newswires (medical and/ or oncology news) 
• Medical Journals 
• Pharmaceutical Companies 
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Table 3.1-1: Details of information sources provided by FDA 
Name URL Information 
FDA 
Homepage www.fda.gov see CDER 
http://www.fda.gov/cder/ 
CDER 
Homepage 
http://www.fda.gov/cder/Offi
ces/OODP/default.htm 
1) CDER Listserv mailing lists 
(one weekly email containing 
new updates to CDER website)
2) OODP – Office of Oncology 
Drug products (occasional 
notifications of new approvals, 
meetings, presentations, and 
other information from OODP 
– see “What’s New” 
FDAnews http://www.fdanews.com/ 
2 free newsletter available via 
email after free subscription 
(FDAnews is the premier 
provider of domestic and 
international regulatory, 
legislative and business news 
and information for executives 
in industries regulated by the 
U.S. Food and Drug 
Administration) 
1) FDAnews Drug Daily 
Bulletin* 
2) RxTrials Institute Drug 
Pipeline Alert** 
*targeted FDA regulatory, legislative and business news briefs in the pharmaceutical 
and biologics industries (daily newsletter) 
**latest news on research and development of new drugs in high-cost therapeutic ar-
eas such as oncology/haematology, cardiovascular, paediatrics, respiratory 
and others; issues cover U.S. and international clinical trials, medical re-
search, drug applications and co-development activities (weekly newsletter) 
 
EMEA – European Medicines Agency 
The European Medicines Agency (EMEA) is a decentralised body of the 
European Union with its headquarter in London and was established in 
1995 according to the Regulation (EC) 2309/93. Its main responsibility is 
the protection and promotion of public and animal health through the 
evaluation and supervision of medicines for human and veterinary use [21]. 
The EMEA is responsible for the scientific evaluation of applications for 
European marketing authorisation for medicinal products (centralised pro-
cedure). Under the centralised procedure, companies submit a single mar-
keting authorisation application to the EMEA. Once granted by the Euro-
pean Commission, a centralised (or ‘Community’) marketing authorisation 
is valid in all European Union (EU) and EEAEFTA states (Iceland, Liech-
tenstein and Norway). 
The agency consists of five scientific committees, composed of members of 
all EU and EEAEFTA states, which conduct the main scientific work of the 
Agency: the Committee for Medicinal Products for Human Use (CHMP), 
the Committee for Medicinal Products for Veterinary Use (CVMP), the 
EMEA provides 
information about 
orphan drug 
designations and 
approved medicinal 
products 
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Committee for Orphan Medicinal Products (COMP), the Committee on 
Herbal Medicinal Products (HMPC) and the Paediatric Committee 
(PDCO). A sixth scientific committee – the Committee for Advanced 
Therapies (CAT) – will be established at the end of 2008. Information about 
Orphan medicinal products, applications for new products, positive opin-
ions adopted by the Committee of Medicinal Products for Human Use 
(CHMP) are available on EMEA’s homepage (Table 3.1-2). 
Table 3.1-2: Details of information sources provided by EMEA 
Name URL Information 
EMEA http://www.emea.europa.eu/ 
EMEA Mailing Lists – 3 
newsletters available via 
email 
1) Human Medicinal 
products list* 
2) Orphan Medicinal 
products list** 
3) Press Releases*** 
(CHMP, COMP) 
* Information about authorised products, Opinion Summaries, Product safety Alerts, 
Market Withdrawals, Referrals, Orphan Medicinal Products, Herbal Medici-
nal Products Guidance Documents 
** Information about Orphan Product Designation, Orphan Incentives, Committee 
for Orphan Medicinal Products (COMP), Quality Management 
*** EMEA Press Releases, Management Board Press Releases, CHMP Press Releases, 
CHMP Product Safety announcements, COMP Press Releases, HMPC Press 
Releases, CVMP Press Releases, CVMP Product Safety announcements, 
PDCO Press Releases 
 
PMPRB – Patented Medicine Prices Review Board 
The Patented Medicine Prices Review Board (PMPRB) is an independent 
quasi-judicial body established by the Canadian Parliament in 1987 under 
the Patent Act (Act). The PMPRB has a dual role, a regulatory role to pro-
tect consumers and contribute to Canadian health care by ensuring that 
prices charged by manufacturers for patented medicines are not excessive 
and a reporting role to contribute to informed decisions and policy making 
by reporting on pharmaceutical trends and on the R&D spending by phar-
maceutical patentees. In Canada, Health Canada assesses new medicines to 
ensure that they conform to the Food and Drugs Act and Regulations and 
the PMPRB is responsible for regulating the prices [22].  
The PMPRB released its first New Drug Pipeline Monitor (NDPM) in June 
2007. The NDPM is a new web-based, semi-annually publication that sum-
marizes information on new drugs that are expected to be launched in Can-
ada within the next two to five years and could potentially have a significant 
impact on federal, provincial and territorial (F/P/T) drug plan expenditures 
(Table 3.1-3). 
Canadian agency for 
drug price regulation 
releases semi-annually 
Drug Pipeline Monitor 
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Table 3.1-3: Details of PMPRB Homepage 
Name URL Information 
New Drug Pipeline 
Monitor by PMPRB 
http://www.pmprb-
cepmb.gc.ca/ 
Bi-annual publication of 
NDPM – available as 
PDF-format on the 
PMPRB homepage in 
June and December 
 
3.1.3 Societies of Clinical Oncology 
ASCO – American Society of Clinical Oncology 
The American Society of Clinical Oncology (ASCO) is a non-profit organiza-
tion, founded in 1964, with overarching goals of improving cancer care and 
prevention. ASCO is the world’s leading professional organization represent-
ing physicians who treat people with cancer. ASCO’s members set the stan-
dard for patient care worldwide and lead the way in carrying out clinical re-
search aimed at improving the prevention, diagnosis, and treatment of can-
cer [23].  The ASCO Annual Meeting is the premier event in the oncology 
community and the research and education presented at ASCO meetings 
enhance oncologists’ knowledge, thereby advancing high-quality cancer care. 
ASCO’s homepage contains a lot of oncology-related news and reports (Ta-
ble 3.1-4). 
Table 3.1-4: Details of ASCO Homepage 
Name URL Information 
ASCO www.asco.org 
1) see News – Cancer News - 
professionals (Headline news on the 
latest cancer research) 
2)  Annual ASCO Meeting*  – 
Abstracts and “virtual meeting” are 
available on the homepage 
*Comprehensive database of Annual Meeting abstracts and online access to lec-
ture/slide presentations and posters from ASCO Annual Meetings 
 
German Society of Cancer (Deutsche Krebsgesellschaft) 
The German Society of Cancer (Deutsche Krebsgesellschaft, DKG) is the 
leading scientific-oncological society in Germany and is based in Berlin. Ex-
tensive interesting and useful information regarding meeting-highlights in 
oncology and anticancer drug research are available with a free subscription 
(DocCheck-password [24]) on the society’s homepage (Table 3.1-5). 
leading Society in 
oncology provides 
relevant cancer news 
society in oncology 
provides relevant cancer 
news for Germany 
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Table 3.1-5: Details of German Society of Cancer 
Name URL Information 
Deutsche 
Krebsgesellschaft 
e.V. 
www.krebsgesellschaft.de/ 
News and Meeting-
Highlights* 
1) A¨rzte – Aktuelles - 
Nachrichtenu¨berblick 
2) A¨rzte - 
Kongressberichte 
(access with DocCheck 
Password) 
* No English version available 
 
ISOPP – International Society of Oncology Pharmacy 
Practitioners 
The International Society of Oncology Pharmacy Practitioners (ISOPP) will 
promote and enhance oncology pharmacy practice worldwide in order to 
improve cancer patient care. The ISOPP website contains relevant cancer 
therapy-related news (Table 3.1-6). 
Table 3.1-6: Details of ISOPP 
Name URL Information 
ISOPP www.isopp.org 
Cancer News are 
available on its 
homepage 
 
3.1.4 Clinical Trial Registries 
ClinicalTrials 
ClinicalTrials.gov is a registry of federally and privately supported clinical 
trials conducted in the United States and around the world. ClinicalTri-
als.gov gives information about a trial's purpose, who may participate, and 
locations. ClinicalTrials.gov is a Service of the U.S. National Institute of 
Health. ClinicalTrials.gov contains thousands of studies and new clinical 
trials are received daily but there is an option to search free of charge within 
the recently (within the last 60 or 14 days) added studies (Table 3.1-7). 
Table 3.1-7: Details of Clinicaltrials.gov 
Name URL Information 
ClinicalTrials www.clinicaltrials.gov 
recently added studies 
can be easily searched  - 
see “What’s new” – added 
the last 60 or 14 days 
(sort by condition 
“cancer/neoplasm”) 
 
cancer therapy-related 
news service 
information about 
ongoing and completed 
clinical trials for 
anticancer drugs 
Horizon Scanning in Oncology 
24 LBI-HTA | 2008 
3.1.5 HTA Agencies with existing Horizon  
Scanning Systems 
The following institutions are adept at Horizon Scanning activities and pro-
vide useful information about new/ emerging technologies including anti-
cancer drugs on their homepages.  
EuroScan 
EuroScan (International Information Network on New and Changing 
Health Technologies) is a collaborative network of health technology as-
sessment agencies to exchange information and to evaluate emerging tech-
nologies [8]. Since the first meeting of EuroScan members in February 1998, 
the collaboration has been working together to promote a common under-
standing of early warning activities, develop the methodology involved in 
this discipline and produce a system in which experiences and findings can 
be shared. EuroScan developed a publicly-accessible search of the EuroScan 
database to facilitate access to reports published by member agencies (Table 
3.1-8). 
NHSC – National Horizon Scanning Centre 
The National Horizon Scanning Centre (NHSC) is a member of EuroScan 
and part of the National Institute for Health Research. NHSC hosts the se-
cretariat of EuroScan. The NHSC aims to provide advanced notice to the 
Department of Health and national policy makers in England of selected 
new and emerging health technologies (including changing applications and 
uses of existing technologies) that might require urgent evaluation, consid-
eration of clinical and cost impact or modification of clinical guidance 
around 2-3 years prior to launch on the National Health Service in UK. 
Technology Briefings and notes produced by the NHSC since January 2000 
are available on its homepage (Table 3.1-8). 
CADTH – Canadian Agency for Drugs and Technologies in 
Health 
The Canadian Agency for Drugs and Technologies in Health (CADTH) is 
an independent, not-for-profit agency funded by Canadian federal, provin-
cial, and territorial governments to provide credible, impartial advice and 
evidence-based information about the effectiveness of drugs and other 
health technologies to Canadian health care decision makers. CADTH is a 
member of EuroScan. A Horizon Scanning Service which alerts decision 
makers to new and emerging health technologies that are likely to have a 
significant impact on the delivery of health care in Canada exist since 1997 
within the Health Technology Assessment Program (HTA). 
The Canadian Agency for Drugs and Technologies in Health’s horizon 
scanning products include “Issues in Emerging Health Technologies” and 
“Emerging Drug List” (Table 3.1-8). Issues in Emerging Health Technolo-
gies is a series of concise bulletins describing drug and non-drug technolo-
gies that are not yet used (or widely diffused) in Canada. Emerging Drug 
List is an online series that profiles new drugs and vaccines while they are at 
an early stage of development, prior to Health Canada approval. Both issues 
international 
collaboration, 
development of 
methodology and 
common understanding 
service for Department 
of Health and national 
policy makers in 
England  
different products: 
Emerging Health 
Technologies, Emerging 
Drug List  
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are available to be downloaded in an electronic format (PDF) on CADTH’s 
Homepage [25]. 
Table 3.1-8: Details of HTA Agencies with existing HSS 
Name URL Information 
EuroScan http://www.euroscan.bham.ac.uk/ See “Technology Reports” 
NHSC http://pcpoh.bham.ac.uk/public health/horizon/index.htm 
See “Technology 
Briefings” – restriction 
to „Cancer“  
http://www.cadth.ca 
General homepage – see 
Horizon Scanning 
Program 
CADTH 
http://www.cadth.ca/index.php/ 
en/hta/programs/horizon-scanning 
1) Issues in Emerging 
Health Technologies 
2) Emerging drug list 
Both issues can be 
downloaded as 
electronic version (PDF)
 
3.1.6 Newswires  (Cancer/ Oncology/ Medical News) 
Several internet information sources which provide oncology-related, cancer 
or medical news can be used for identifying new/ emerging anticancer drugs 
(Table 3.1-9). 
Cancer Consultants Professionals 
Cancer Consultants, Inc. is a company that developed the oncology e-space. 
Cancer Consultants has been producing and distributing cancer information 
for patients and professionals since 1998. The purpose of Cancer News is to 
provide summaries of new treatment strategies as they are discovered and 
reported by cancer physicians around the world. Original news summaries 
from peer-reviewed journals and oncology meetings are provided daily. 
PharmaLive – R&D News 
PharmaLive provides broad coverage of pharmaceutical business, product 
marketing, and clinical research information. It is a product of the Canon 
Communications Pharmaceutical Media Group and since 1995 R&D Direc-
tions are published which provides extensive coverage of pharmaceutical 
product development and insight into successful R&D strategies. 
Therapeutics daily - Oncology 
Therapeutics Daily – Oncology provides news and information focusing on 
the development, sales, and marketing of medicines that treat cancer. It is a 
product of the Canon Communications Pharmaceutical Media Group too 
and created by PharmaLive. 
 
internet information 
sources which provide 
cancer news from 
clinical trials and 
industry for health 
professionals on new 
treatment strategies 
gives insight in  
R&D strategies 
on development, sales, 
and marketing  
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PhRMA – Medicines in Development Database 
PhRMA represents the leading Pharmaceutical Research and Manufacturers 
of America and provides a database with includes medicines currently in 
clinical trials or at the FDA for review. 
Medscape Haematology-Oncology News 
Medscape offers specialists, primary care physicians, and other health pro-
fessionals timely comprehensive and relevant clinical information. One spe-
ciality site includes daily haematology-oncology news. Medscape is organ-
ized by medical specialty, with each supported specialty having its own cus-
tomized website. Specialty content is evaluated, created, and presented un-
der the guidance of a Medscape program director and a medical professional 
advisory board 
Medknowledge 
Medknowledge-Germany provides information about medicine in Germany 
e.g., new drugs in pipeline. 
Drug Information Online 
Drugs.com is a popular, comprehensive and up-to-date source of drug in-
formation online. It presents independent information in a clear and concise 
format for healthcare professionals and complies with the HONcode stan-
dard for trustworthy health information. 
Pharmatrix 
Pharmatrix provides independent information on drugs in development or 
newly approved in Germany and other countries for health professionals. 
Pharmatrix complies with the HONcode standard for trustworthy health in-
formation. 
NeLM 
The National electronic Library for Medicines (NeLM) (formerly known as 
DrugInfoZone) provides timely and relevant information on medicines and 
support prescribing to the NHS at the point of care. The NeLM is part of the 
National Library for Health (UK).  
The Ones to Watch 
Thomson Reuters provides a quarterly review of the latest phase changes in 
the pharmaceutical pipeline in “The Ones to Watch”. 
database of medicines in 
trials  
daily news on 
haematology-oncology  
Germany only 
independent 
independent, Germany 
only 
medicines in Great 
Britain 
drugs in pipeline 
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Table 3.1-9: Details of selected Newswires related to oncology 
Name URL Information 
CancerConsultants  - 
Physician Resource 
Centre 
http://professional.cancer 
consultants.com/ 
See „conference 
coverage“ and „cancer 
news” and Physician 
Resources – Drug 
Pipeline 
PharmaLive  www.pharmalive.com 
see „Today’s News -
R&D News” – 
information about 
Drug Approvals, Drug 
Discovery und Drugs 
in Development 
Therapeutics daily – 
Oncology 
http://www.therapeutics 
daily.com/ 
Choose channel 
“oncology” – a daily 
newsletter is available 
via email after free 
registration 
PhRMA http://www.phrma.org 
See „Medicines in 
Development“ -„search 
database“  
restrict indication to 
“cancer” and choose 
„any company“  and 
“any stage” 
Medscape 
Haematology – 
Oncology News 
http://www.medscape.com/hemat
ology-oncology/news 
a daily newsletter is 
available via email 
after free registration
Medknowledge http://www.medknowledge.de/ 
a weekly newsletter is 
available via email 
after free registration
Drug Information 
Online http://www.drugs.com 
See “Pharmaceutical 
News & Articles” - 
Pharma News, new 
drug approvals and 
clinical trials 
a monthly newsletter 
is available via email 
after free registration
Pharmatrix www.pharmatrix.de 
free registration with 
DocCheck Password 
via klinik-plus.de 
see „neue 
Arzneimittel“  
NeLM – National 
electronic library for 
medicine 
http://www.nelm.nhs.uk 
See “latest news” and 
„categories – 
medicines information 
– Horizon Scanning“  
(licence extension) 
a daily newsletter is 
available via email 
after free registration
The Ones to watch 
http://www.scientific.thomson.co
m/pharma/forms/ 
matters/ 
A quarterly report 
about drugs in 
development is 
available via email 
after free registration
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3.1.7 Medical Journals 
High quality medical journals are an important source for clinical experts to 
stay informed about medical progress. Based on clinical experts’ sugges-
tions, we therefore included 11 medical journals as potential information 
sources within our HSS (Table 3.1-10). We didn’t subscribe to all journals 
but they offer a free email alerting service (eContent Alert service or Tables 
of Contents and Announcements – eTOC service). After subscribing, this 
free service sends out alerts by e-mail whenever new content in the selected 
journal is published. The table of contents of each journal can then be 
scanned easily.  
Table 3.1-10: Details of selected Medical Journals 
Name URL Information 
American Journal of 
Clinical Oncology 
http://www.amjclinical 
oncology.com eContent Alert available
Annals of Oncology 
http://annonc.oxford 
journals.org/current.dtl 
eContent Alert available
Cancer Treatment 
Reviews 
http://intl.elsevierhealth.com/
journals/ejca 
eContent Alert available
European Journal of 
Cancer  
http://www.sciencedirect.com/
science/journal/09598049 
eContent Alert available
Journal of Clinical 
Oncology 
http://jco.ascopubs.org/content/
vol25/issue7/ eTOC available 
The Lancet 
Oncology 
http://www.sciencedirect.com/
science/journal/14702045 eContent Alert available
Blood 
http://bloodjournal.hemato 
logylibrary.org 
eTOC available 
Nature Medicine 
http://www.nature.com/nm/ 
index.html 
eTOC available 
 (topics: oncology / hae-
matology / oncology 
medicine 
The Lancet http://www.thelancet.com/ eContent Alert available
NEJM http://content.nejm.org/ eTOC available 
Expert Opinion on 
Emerging Drugs 
http://www.expertopin.com/ 
toc/emd/12/2 
eTOC available 
11 different medical 
journals included  
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3.1.8 Pharmaceutical Companies 
International pharmaceutical companies provide detailed information about 
their research and development activities concerning new drugs in their so-
called R&D or pipeline section. We included homepages of 31 well-known 
manufacturers of anticancer drugs in our scanning process (Table 3.1-11.) 
although updates of the provided information are often poor. 
Table 3.1-11: Details of included homepages of Pharmaceutical Companies 
Name URL Information 
Amgen 
http://www.amgen.com/science/ 
pipe.jsp 
see Science - Pipe-
line 
Antigenics 
http://www.antigenics.com/ 
products/pipeline/ 
see products & 
technologies - 
product pipeline 
ArQule http://www.arqule.com/res/pip/ 
see product R+D - 
pipeline 
AstraZeneca 
http://www.astrazeneca.com/ 
article/511390.aspx 
see research - pipe-
line summary 
Bayer Schering 
http://www.bayerschering 
pharma.de/scripts/pages/ 
de/forschung_und_entwick 
lung/entwicklungsprojekte/ 
index.php 
See Research and 
Development – 
Projects- - Pipeline 
Overview 
Bioenvision 
http://www.bioenvision.com/ 
products_pipeline.php 
see products - 
product pipeline 
Boehringer-
Ingelheim 
http://www.boehringer-
ingelheim.com/ 
corporate/research/ 
rd_areas_oncology.htm 
see Research and 
Development - 
R&D areas -  
oncology 
Bristol Myers Squibb 
http://www.bms.com/research/ 
content/data/pipeline.html see R&D - pipeline
Cell Therapeutics 
http://www.cticseattle.com/ 
products.htm 
see products - pipe-
line 
Cephalon 
http://www.cephalon.com/ 
cephalon_science/pipeline.aspx 
see Science - Pipe-
line 
Celgene Corporation 
http://www.celgene.com/research/
drug-research-and-develop 
ment-home.aspx 
see research & de-
velopment - pipe-
line 
Cytogen Corporation 
http://www.cytogen.com/products/
index.php 
see products - pipe-
line 
Dendreon 
http://www.dendreon.com/dndn/ 
pipeline 
see pipeline 
Genentech 
http://www.gene.com/gene/ 
pipeline/status/ 
see development - 
pipeline 
information from 31 
different 
pharmaceutical 
companies about their 
R&D activities in 
oncology 
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Genzyme 
http://www.genzyme.com/research/pi
peline/pipe_home.asp 
see or research - re-
search pipeline 
GlaxoSmithKline 
http://www.gsk.com/investors/ 
pp_pipeline_standard.htm 
see investors - 
product portfolio - 
pipeline 
ImClone Systems In-
corporated 
http://www.imclone.com/ 
clinical.php 
see clinical devel-
opment 
Lilly Oncology 
http://investor.lilly.com/ 
pipeline.cfm 
see investors - 
product pipeline 
Merck KGaA http://www.merck.com/ 
see Merck - pipe-
line 
MGI Pharma 
http://www.mgipharma.com/ 
wt/page/pipeline 
see pipeline 
Millennium 
Pharmaceuticals 
http://www.mlnm.com/rd/ 
pipeline/index.asp see R&D - pipeline
Novartis Oncology 
http://www.novartisoncology.com/ 
research-innovation/ 
pipeline.jsp?usertrack.filter_ 
applied=true&NovaId= 
1178761751543863717 
see research - re-
search innovation - 
pipeline 
Onyx Pharmaceuti-
cals 
http://www.onyx-
pharm.com/wt/page/ 
clinical_pipeline 
see clinical devel-
opment - clinical 
pipeline 
Ortho Biotech 
http://www.orthobiotech.com/ 
products.html 
see products & ser-
vices 
OSI Oncology 
http://www.osip.com/ 
products_oncology 
see products & 
pipeline - oncology
Pfizer 
http://www.pfizer.com/research/ 
pipeline.jsp 
see research & de-
velopment - pipe-
line 
Pharmacyclics 
http://www.pharmacyclics.com/ 
wt/page/programs 
see therapeutic 
programs 
Roche 
http://www.roche.com/home/ 
science/sci_prod/ 
sci_prod_pharmap.htm 
see R&D - product 
pipeline - pharma-
ceuticals 
Sanofi-Aventis 
http://en.sanofi-aventis.com/ 
rd/portfolio/ 
p_rd_portfolio_oncology.asp 
see our research - 
R&D portfolio - on-
cology 
Schering-Plough 
http://www.schering-
plough.com/schering_plough/ 
research/spri/index.jsp 
see R&D (products 
in development) 
Ziopharm 
http://www.ziopharm.com/ 
clinical_dev.php 
see clinical devel-
opment 
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3.2 Scanning Process 
Within the selection process (see chapter 2.3) of information sources we con-
currently determined the frequency of information update carried out by 
each website. In preparation of the later arranged feasibility study we in-
stalled a separate email account for our project called ‘hss-
onko@hta.lbg.ac.at’ which could be used for subscriptions to eContent 
Alerts and listservs and where all emails from our information sources could 
be collected for the scanning process. Afterwards, over a period of two weeks 
we concentrated on making ourselves familiar with each website by scanning 
the sources daily and collecting data on new/ emerging anticancer drugs. 
Due to our experiences from this testing phase and the availability of eCon-
tent Alerts and listservs via email from several providers we preliminarily 
decided to scan the above mentioned information sources from the catego-
ries Regulatory Authorities, Societies of Oncology, Clinical Trial Registries, 
HTA Agencies with existing HSS, Newswires (medical and/ or oncology 
news) and medical Journals once a week. Homepages of pharmaceutical 
companies are scanned only once a month because of rare updates. The du-
ration of the whole process depends on the amount of emails received and 
the amount of data on new/ emerging anticancer drugs which should be ex-
tracted (see below). 
3.3 Data Extraction 
During the scanning process any data on new/ emerging anticancer drugs 
according to the defined inclusion criteria (see chapter 2.1.) were collected 
and tabulated in a previously prepared Excel spreadsheet. We collected data 
concerning the following parameters:  
b Drug name (brand name, if available) 
b Company/developer 
b Short drug description (drug class, mode of action) 
b Patient indications 
b Approximate number of patients with disease in Austria (Source: Sta-
tistics Austria [1]) 
b Stage of development 
b Has the technology already been approved in the EU for other indica-
tions (incl. orphan drug status) or by the FDA? 
b Costs in Euro € (if available) 
The aim of data extraction is to gather basic information of sufficient quality 
on new/ emerging anticancer drugs and their applications. Finally, the ex-
traction sheet should comprise a detailed description of all identified anti-
cancer drugs and should be appropriate for our expert panel to apply the de-
fined prioritisation criteria (i.e. to enable subsequent priority setting). 
The scanning and data extraction process can be summarized as follows:  the 
optimal and necessary scanning frequency is set at once a week and once a 
month for the companies’ websites. The time which is needed to scan the 63 
weekly scanning of 
information sources on 
the Internet, eAlerts and 
eNewsletters 
collection of detailed 
information about 
identified anticancer 
drugs 
permanent scanning, 
identification and 
extraction of data: 6-10 
hours per week 
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sources and to extract data on identified anticancer drugs fulfilling the in-
clusion criteria spans from 6 to 10 hours a week. 
3.4 Priority Setting Criteria 
Based on four predefined categories (i.e., phase of development, indication, 
drug description, clinical/ economic impact), the criteria collected from lit-
erature [10-13] and after consultation with our clinical experts, we deter-
mined a final priority setting instrument of seven criteria (Table 3.4-1). 
Each criterion has several answer options with a deposited score ranging 
from 0 to 2 (3). We did not weight our criteria (each criterion was defined as 
equivalent to the others and none of the criteria was more important than 
the others). 
Table 3.4-1: Criteria for Priority Setting 
criterion answer options score 
it is already avail-
able/adopted 
0 
in 0-2 years 2 
in 2-4 years 1 
1) When does the technology appear 
likely to be launched in Austria/in 
the EU? 
in 4 or more years 0 
high 2 
moderate 1 
low 0 
2) Burden (severity) of disease 
(mortality, morbidity, quality of life)
unknown 0 
more than 1000 3 
500-1000 2 
100-500 1 
3) Estimated number of patients 
with disease in Austria (per year) 
0-100 0 
yes 2 
no 0 
4) Is this an innovative drug for a 
disease with no satisfactory standard 
treatment? don’t know 1 
major 2 
moderate 1 
minor 0 
5) Is there potential for a significant 
health benefit to the patient group 
(high clinical impact)? 
unknown 0 
major 2 
moderate 1 
minor 0 
6) Is there potential for a significant 
impact on hospital drug budgets if 
the technology diffuses widely (be-
cause of expected moderate to high 
unit costs and/or because of high pa-
tient numbers)? 
unknown 0 
major 2 
moderate 1 
minor 0 
7) Is there potential for inappropri-
ate diffusion (too fast or too slow) 
or use (off-label) of the technology?
unknown 0 
 
seven criteria with an 
underlying score were 
included in our priority 
setting instrument 
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The maximum score which could be obtained is 15 and the following cut-off 
points were chosen to define high relevant anticancer drugs:  
b Score 10-15: highly relevant drugs which should be considered for 
early assessment 
b Score 5-9: drugs which should be monitored 
b Score 0-4: drugs which should be dropped 
 
3.5 Feasibility Study 
3.5.1 Procedure 
From January 1, 2008 to March 31, 2008 one person scanned the selected in-
formation sources and the information received via email (eNewsletters, 
eTOCs) weekly. Data on new and emerging anticancer drugs were collected 
and entered into the prepared Excel spreadsheet. The weekly scanning and 
data extraction process took approximately 8 hours. Subsequent to the 3-
month scanning period, the extracted data were revised and adapted to the 
experts’ needs for the prioritisation process. Finally, after removal of dupli-
cates (overlap in results from different information sources) we obtained a 
list of 140 hits comprising 116 different anticancer drugs. This difference 
indicates that some drugs are in development for various indications. About 
90 out of the 140 hits are in development stage clinical trial phase II. The 
preparation of this final extraction sheet took an additional 8 hours. 
3.5.2 Results 
From April to the beginning of May the prioritisation step was carried out, 
with the aim to narrow down the original list to a manageable amount of 
anticancer drugs to be subjected to further evaluation. The whole list (Excel 
Spreadsheet) in alphabetical order was sent to our expert panel who applied 
individually the predefined prioritisation criteria to the 140 hits and who 
commented on the feasibility of the instrument and the HSS in general. The 
completed lists from our 3 experts were then analysed separately by translat-
ing and quantifying their answers into the corresponding achieved scores 
(see Table 3.4-1): Each item received a score from each expert depending on 
the respective selected answer options. The results were compared to each 
other. Then a mean score was calculated for each anticancer drug to achieve 
a final ranking. The analysis resulted in a narrowed list comprising the 5 
highest scoring drugs which should be considered for further evaluation. 
Figure 3.5-1 shows the results from the prioritisation process. 
 
 
 
 
 
drugs with a score of 10 
to15 are considered for 
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identification of 116 
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drugs within a scanning 
period of 3 months 
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Figure 3.5-1: Results of the prioritisation process 
The detailed results (single and mean score for the 140 hits respectively 116 
different anticancer drugs) from the prioritisation process by the 3 clinical 
experts is provided in the appendix (see chapter 7). The results have to be 
interpreted carefully because there was to some extent great variability in 
the prioritisation by the individual experts and they reported several unex-
pected difficulties while working hands-on with the provided data and the 
priority setting instrument (see chapter 3.5.3). The calculation of a mean 
score for each anticancer drug was not leading to useful results and therefore 
was an insufficient method. According to Douw and Vondeling [11] in most 
HSS the final decision on which anticancer drugs to assess is based on 
agreement by consensus, this could therefore be an additional step in our 
priority setting process . 
3.5.3 Experts’ Comments on the Procedure 
An additional task of our expert group was to comment on the feasibility of 
the proposed procedure regarding the following important parts of a HSS: 
Sources and provided information on anticancer drugs 
Although the time period of scanning the selected information sources was 
only three months, the specified information sources seem to be suitable for 
an HSS in oncology. Some information from different sources about anti-
cancer drugs was still overlapping so that in the context of a continuous 
scanning process the sources for identification should be monitored and if 
necessary, supplemented by others or reduced by redundant ones. 
usefulness of results is 
limited by clear 
differences in 
prioritisation by experts: 
consensus proposed 
Final classification – after prioritisation 
by 3 experts (according the mean score) 
Score 10-15:  n= 5 
Score 5-9:  n= 94 
Score 0-4:  n= 41 
Total hits 
n = 140  
(116 different anticancer 
drugs) 
Results 
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The parameter for data extraction (see chapter 3.3) were chosen adequately 
but extracted data sometimes were not detailed enough to apply the priority 
setting criteria. Especially the parameters “drug description” and “patients’ 
indication” should be filled out in more detail and short information on pre-
liminary efficacy results from clinical trials should be mentioned. All ex-
perts had to use additional sources (e.g. publications, meeting abstracts) to 
get an idea about the efficacy of the described anticancer drugs. In addition, 
more precise incidence or prevalence data regarding Austria for the de-
scribed diseases would be helpful. 
Identified anticancer drugs 
A lot of drugs for cancer treatment appear on the horizon but never reach 
market entry. Especially in oncology many drugs which are tested in clinical 
phase II trials fail to enter the more important phase III trials because they 
are lacking positive efficacy results. Identifying and selecting all drugs in 
development stage phase II is not necessary because only results from com-
pleted clinical trials phase II determine the drugs’ future. Experts suggested 
as a kind of filtering instrument prior to the real prioritisation process to 
concentrate on anticancer drugs with positive phase II results from com-
pleted clinical trials, on drugs with FDA fast track designation or with 
FDA/ EMEA Orphan drug designation and on drugs currently in clinical 
trials phase III or in the phase of adoption. 
Comments on prioritisation criteria 
In general, the defined priority setting instrument was applicable and use-
ful, but criteria 4, 6 and 7 (see chapter 3.4) should be specified more pre-
cisely to ensure a consistent prioritisation by different experts: 
b Criterion 4 “innovative drug for a disease with no satisfactory stan-
dard treatment”: A suggestion was made to divide the question into 
one for “innovative drug” and one for “disease with no satisfactory 
treatment”, because these two features are not necessarily linked  
b Criterion 6 “impact on hospital drug budgets”: this should be dis-
cussed further because some new anticancer drugs also affect social 
insurance budgets due to their using oral applications and requiring 
prescriptions for outpatients; for most drugs no cost information was 
available. Therefore, the expert panel should discuss how to deal with 
missing cost data 
b Criterion 7 “potential for inappropriate diffusion”: the experts should 
elaborate on what inappropriate diffusion could be concerning anti-
cancer drugs e.g. reasons for off-label use 
Furthermore, all comments mentioned that positive efficacy results from 
preliminary clinical trials should be the most important criterion for selec-
tion and further considerations. Therefore, the use of weighted criteria must 
be discussed. 
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Comments on the prioritisation process and the size of the expert panel 
On average the experts needed about 4 hours to apply the priority setting 
criteria to the 140 identified items, but could have needed longer if more in-
formation had been available. Due to the high number of drugs in develop-
ment phase II, the lacking efficacy information and the imprecise definition 
of some criteria, experts could not do an unambiguous prioritisation. The 
exchange of information on the identified drugs in the context of periodical 
joint meetings or by using the Delphi technique would be necessary to reach 
a consensus on the most relevant new/ emerging anticancer drugs which 
should be considered for early assessment and finally for decision making 
and prospective budget planning. In addition, they mentioned that three ex-
perts might not be able to cover the wide field of developments in haematol-
ogy and oncology and they suggested constituting a more specific expert 
panel (e.g. separate experts for solid tumours, haematological neoplasm and 
for the large cancer entities like e.g. breast cancer, lung cancer, colorectal 
cancer) to improve the prioritisation process. 
3.6 Early Assessment 
The step of early assessment was not part of our feasibility study, but we 
compared different formats from three well-known agencies with HSS and 
propose a method which has to be explored and discussed within the next 
steps of our HSS concept (see chapter 4.3). 
3.6.1 Format 
We compared the formats from Danish Health Technology Alerts (Danish 
Centre for Evaluation and HTA), from NHSC’s Technology briefings and 
Canadian Emerging Drug Lists (CADTH) to get an idea about a suitable 
approach for our HSS in oncology (Table 3.6-1). 
 Table 3.6-1: Comparison of different formats (selection, not exhaustive) 
multistage process and 
more experts with 
expertise in specific 
tumour entities 
method of early 
assessment will be 
explored as one of the 
next steps 
 Danish Health Technology Alert Technology briefings (NHSC) Emerging Drug List (CADTH) 
Content  
structure 
Summary 
Disease 
Current treatment 
New treatment 
Use in Denmark 
Evidence (efficacy, safety) 
Ongoing trials 
Costs 
Implementation  
References 
Target group 
Technology description 
Innovation 
Place of use 
Availability 
Relevant guidance 
Clinical need/ burden of disease 
Existing treatments 
Efficacy/ safety 
Estimated costs 
Potential impact 
References 
Indication 
Current regulatory status 
Description 
Current treatment 
Cost 
Evidence (efficacy, safety)
Commentary 
References 
Length 4 pages 6 pages 4 pages 
Results 
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An early assessment should summarize the best available evidence to esti-
mate in particular clinical and financial consequences of the new/ emerging 
drug. In view of the above mentioned formats of early assessments, we sug-
gest the following structure and a length of 4 to 6 pages depending on the 
amount of available information: 
b Technology description 
b Indication 
b Burden of disease in Austria 
b Current treatment 
b Current regulatory status/ Availability 
b Evidence (efficacy, safety) 
b Ongoing trials 
b Estimated costs 
b Commentary/ recommendation 
b References 
The structure of early assessments should be consistent with the LBI-HTA’s 
internal manual for systematic reviews [26]. One of the challenges of early 
assessment in HSS is the lack of evidence and the limited access to informa-
tion on new technologies. Therefore, the involvement of pharmaceutical 
companies to provide information should be considered to ensure the inclu-
sion of comprehensive data on the selected new/ emerging anticancer drug 
for early assessment. 
3.6.2 Process and Dissemination 
Early assessments will be performed by the LBI-HTA. The number of as-
sessments produced will depend on the resources available and the number 
of relevant anticancer drugs considered for early assessment per year. Peer 
review is already a standard process at the LBI-HTA and should also be per-
formed for early assessments to guarantee high quality output. The detailed 
process has to be discussed further and explored by applying the method to 
concrete examples of relevant anticancer drugs. The aim should be to gener-
ate a standardized, transparent and systematic method for conducting early 
assessments in accordance with already existing methods at the LBI-HTA 
[26]. 
The dissemination of reports is the final step of our HSS. Potential target 
groups of our Horizon Scanning reports are health professionals, hospital 
administrators, drug commissions and social insurance organisations. The 
final dissemination strategy yet to be defined but could include individual 
communication with decision makers, announcements within our monthly 
HTA newsletter, presentations in the context of our quarterly ‘HTA in hos-
pital-meetings and online availability at the LBI-HTA’s publication index. 
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4 Discussion 
4.1 Concept of Horizon Scanning in Oncology 
This concept provides a basis for discussion on the implementation of an 
Austrian Horizon Scanning System in oncology. Based on a literature search 
and advice from experts, we developed a concept of a HSS which focuses on 
anticancer drugs and tested the feasibility of its two main steps: identifying 
new/ emerging anticancer drugs and determining their priority rating.  
The principle structure of the Horizon Scanning System is well defined but 
the feasibility study showed that further improvements are necessary to en-
sure an effective HSS. In particular, revisions could be made in the proce-
dures for collecting data for new/ emerging anticancer drugs and for priori-
tising medicines by clinical experts. For the latter, two important aspects 
have to be considered: first, the size and composition of the expert panel, 
and second, the priority setting instrument itself, because the priority set-
ting process is highly dependent on the individuals involved in the process 
[12]. A review of Noorani et al.’s comparison of various priority setting ap-
proaches can be used for optimizing our prioritisation method [27]. 
Clinical experts are a key element of the HSS but their ability to predict an 
anticancer drug’s impact remains unclear. A recent study concluded that in-
formation from experts may be valuable as part of a process aimed at effi-
ciently selecting technologies for evaluation [28]. For the expert panel re-
sponsible for the selection of anticancer drugs for further evaluation, we 
suggest involving several clinical experts with specific expertise in one sin-
gle clinical speciality of oncology (e.g., lung cancer, breast cancer) to ensure 
a more certain and valid selection of relevant anticancer drugs.  Due to the 
fact that priority setting is the most critical step within the HSS (i.e. to miss 
an important drug or to select unimportant ones) we have to re-adapt our 
criteria (e.g., using weighted criteria), to introduce a multistage process and 
to provide clinical expert training and time to adapt to the priority setting 
instrument [11].  
Murphy et al. investigated the important characteristics and components of 
an effective early warning system and the results can be used as a guide for 
setting up such a system [29]. Our HSS should be designed to comply with 
the following five characteristics that were identified as fundamental (i.e. 
highly important) and crucial: 
b The information in the early warning system output should be rele-
vant to the customer in terms of the finally assessed anticancer drugs 
having an impact on Austrian hospitals (clinical and financial conse-
quences) 
b The system should be independent of industrial or commercial influ-
ences: this structural component is already fulfilled by the LBI-HTA 
and will also apply to the HSS which will be part of the agency 
b There should be sufficient funding and staffing of the early warning 
system to enable its aims: that is an important point which must be 
considered before the final implementation of the HSS 
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b A clearly defined route for the system outputs to reach decision mak-
ers must exist: this will be part of the definition of a final dissemina-
tion strategy 
b Defined customers for the system outputs are needed: our project was 
initiated by hospital decision makers who need specific and timely in-
formation about  new anticancer drugs which will have effects on hos-
pital drug budgets; so they are one potential target group for our HSS 
outputs 
4.2 Limitations of the Proposed Concept 
Given the very short amount of time we had to complete our feasibility 
study, we believe our method explored the strengths and limitations of a 
proposed Horizon Scanning System in the best way possible. The main limi-
tations of the proposed concept can be summarized as follows: 
b Information Sources: First, we did not examine overlap between the 
sources. Second, company websites providing limited information on 
emerging anticancer drugs were used as sole source of information 
from the industry on product pipelines instead of direct contact with 
drug companies. 
b Data collection on identified anticancer drugs: First, we did not col-
lect efficacy data from clinical trials which would be necessary for the 
subsequent prioritisation process. Second, in a large part no cost in-
formation for drugs was available.  
b Filtering step: We did not include a filtering step leading to the iden-
tification of a lot of anticancer drugs which are in a very early devel-
opment stage and for which a prioritisation is not feasible. 
b Size of expert panel: First, three clinical experts are unlikely to be 
able to provide appropriate comment on the possible place in therapy 
of all new drugs in oncology. Second, we involved only oncologist. It 
may be of benefit to engage representatives of drug commissions (e.g., 
pharmacologists) in the process. 
b Prioritisation criteria and process: The prioritisation process has not 
turned out satisfactory. The usefulness and its value should be studied 
further. 
Shortcomings could be eliminated by conducting a follow-up feasibility 
study that includes modifications like: a more specific expert panel, a re-
vised priority setting process, inclusion of an early assessment step and in-
volvement by target groups (e.g. hospital managers, drug commissions) in 
the assessment and dissemination process to ensure useful outputs for deci-
sion making (e.g. budget planning, changes in clinical practice). 
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4.3 Approach to Implementation 
A plan to implement an effective HSS at the LBI-HTA should comprise the 
following steps: 
b Setting up of an organizational structure (financial and human re-
source needs and resource planning) 
b Presenting the present concept to experts in HSSs (at HTAi Confer-
ence 2008 in Montreal, Canada) 
b Assembling an extended prioritisation panel comprising clinical ex-
perts with expertise in specific tumours and representatives of drug 
commissions 
b Definition of a filtering step prior to the real prioritisation process 
(e.g., concentration on anticancer drugs with positive phase II results 
from completed clinical trials, discussion of the optimum time hori-
zon) 
b Determining a multistage priority setting process, the definition of 
decision rules/ cut-off points to arrive at an overall judgment on the 
relevance of emerging anticancer drugs, and provision of expert train-
ing in the application of prioritisation criteria 
b Preparing a final concept which includes proposed modifications (e.g. 
inclusion criteria for drugs, more detailed data collection, definition, 
scoring, weighting of prioritisation criteria) 
b Giving presentations to target groups/ customers (e.g. drug commis-
sions) and discussing the format of early assessment and dissemina-
tion strategy 
b Planning and organising a more extensive follow-up feasibility study 
and subsequent evaluation of the HSS and its outputs 
b Starting the regular scanning of the selected information sources 
b Joining EuroScan and exchanging information on new/ emerging 
anticancer drugs with other agencies 
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5 Conclusion 
The HSS, established at a national level, should provide decision makers in 
hospitals with essential information to reduce a premature introduction of 
new anticancer drugs into clinical practice across Austria which can lead to 
patient harms and inadequate use of resources and thereby advance good 
quality and innovative cancer therapy in Austria and elsewhere. 
The establishment of such a HSS should be based on the concept proposed 
as well as considerations arising from the feasibility study results. The op-
eration and output of a HSS will need to be monitored and evaluated to 
judge its value for decision makers. Factors to be weighed include the time-
liness and quality of information on new/ emerging anticancer drugs and 
their potential consequences. 
In any case, each round of scanning is likely to result in the identification of 
fewer new/ emerging anticancer drugs and more often the same drugs will 
be monitored moving through the different stages before market introduc-
tion.  We therefore estimate only 20-30 new entries each year and about five 
qualifying for early assessment.  
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7 Appendix 
Table 7-1: Detailed results from the feasibility study (identified anticancer drugs and their prioritisation by 3 experts
No. Drug name (brand name) 
Company / De-
veloper 
Short Drug descrip-
tion 
Patients’ indica-
tions 
Number of 
patients with 
disease in 
Austria 
(Source: Sta-
tistics Aus-
tria, 2004) 
stage of 
devel-
opment
Is the technology 
already approved 
for other indica-
tions (incl. Or-
phan drug 
status) or by the 
FDA? 
costs in €
NA = not 
available 
COMMENTS
Expert 1 
COMMENTS 
Expert 2 
COMMENTS 
Expert 3 
Score 
E1 
Score 
E2 
Score 
E3 
Mean 
Score 
1 ABT-869 Genentech 
small molecule vas-
cular endothelial 
growth factor 
(VEGF) receptor-
based kinase inhibi-
tor; tablets (oral) 
hepatocellular car-
cinoma (HCC) 
872  
(liver cancer) Phase II No NA    0 7 3 3 
 ABT-869 Genentech 
small molecule vas-
cular endothelial 
growth factor 
(VEGF) receptor-
based kinase inhibi-
tor; tablets (oral) 
in combination 
with paclitaxel, for 
disease progres-
sion in metastatic 
breast cancer 
4832 
(breast can-
cer in 
women) 
Phase II No NA  
maybe an oral 
alternative to 
bevacizumab
 0 12 3 5 
2 Acadesine (Acadra) Protherics 
novel nucleoside ana-
logue, activates 
adenosine mono-
phosphate-activated 
protein kinase 
(AMPK) and induces 
apoptosis 
B-CLL 
964  
(leukaemia, 
all forms) 
Phase 
I/II 
EMEA orphan 
designation since 
2005 
NA  
multiple new 
drugs in CLL 
coming 
 0 4 1 2 
3 ADH-1 Adherex Tech-nologies 
Targets N-cadherin, a 
protein present on 
certain tumor cells 
and established tu-
mor blood vessels. 
in combination 
with melphalan 
for melanoma 
1.169  
(malignant 
melanoma)
Phase IIb
FDA orphan drug 
designation for 
the treatment of 
Stage IIB/C, III, 
and IV malignant 
melanoma, in 
Feb 2008 
NA  
new good 
treatment for 
melanoma ex-
isting 
 0 12 3 5 
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No. Drug name (brand name) 
Company / De-
veloper 
Short Drug descrip-
tion 
Patients’ indica-
tions 
Number of 
patients with 
disease in 
Austria 
(Source: Sta-
tistics Aus-
tria, 2004) 
stage of 
devel-
opment
Is the technology 
already approved 
for other indica-
tions (incl. Or-
phan drug 
status) or by the 
FDA? 
costs in €
NA = not 
available 
COMMENTS
Expert 1 
COMMENTS 
Expert 2 
COMMENTS 
Expert 3 
Score 
E1 
Score 
E2 
Score 
E3 
Mean 
Score 
4 AEZS-108 (AN-152) 
Aetrena  
Zentaris 
a hybrid molecule 
composed of a syn-
thetic peptide carrier 
and doxorubicin, 
LHRH agonist 
LHRH receptor-
positive ovarian 
and endometrial 
cancer 
783 
(ovarian can-
cer) 
951 
(endometrial 
carcinoma) 
Phase II No NA    0 7 2 3 
5 Aflibercept (VEGF-Trap) Sanofi-Aventis 
unique fusion protein 
that binds all forms 
of Vascular Endothe-
lial Growth Factor-A, 
Angiogenesis-
inhibitor 
advanced ovarian 
cancer, third line 
783 
(ovarian can-
cer) 
Phase II No NA  
multiple VGEF 
based thera-
pies under 
way 
 0 8 3 4 
6 Alpharadin Algeta 
radiopharmaceutical 
based on the alpha 
particle emitter ra-
dium-223 
treatment for 
bone metastases in 
hormone-
refractory prostate 
cancer (HRPC) 
5.416 
(prostate 
cancer, ma-
lignant) 
Phase II No NA  
technically 
difficult only 
in major cen-
tres possible 
 0 5 4 3 
7 Alvespimycin Kosan Biosci-ences 
Hsp90-inhibitor (sec-
ond generation) 
HER-2 positive 
metastatic breast 
cancer 
4832 
(breast can-
cer in 
women) 
Phase II No NA    0 13 4 6 
8 Alvocidib (Flavopiridol) Sanofi-Aventis 
cyclin-depending 
Kinase-Inhibitor 
(CDK) 
refractory chronic 
lymphatic leukae-
mia (CLL) 
964  
(leukaemia, 
all forms) 
Phase 
II/III No NA  
multiple new 
drugs in CLL 
coming 
 0 9 3 4 
9 AMG-479 Amgen 
human monoclonal 
antibody that binds 
to insulin-like growth 
factor-1 receptor 
confirmed HR-
positive, locally 
advanced or me-
tastatic breast can-
cer 
4832 
(breast can-
cer in 
women) 
Phase II No NA    0 14 3 6 
10 Amrubicin Pharmion, Cel-gene 
third-generation syn-
thetic anthracycline
small-cell lung 
cancer (SCLC) 
3.864 
(lung cancer, 
all forms) 
Phase III
EMEA orphan 
drug status; FDA 
orphan drug in 
March 2008 for 
SCLC 
NA    8 9 4 7 
11 ARC 197 ArQule 
C-Met Inhibitor, 
orally administered 
drug 
pancreatic cancer
1.388 
(pancreatic 
cancer) 
Phase II No NA    0 10 5 5 
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No. Drug name (brand name) 
Company / De-
veloper 
Short Drug descrip-
tion 
Patients’ indica-
tions 
Number of 
patients with 
disease in 
Austria 
(Source: Sta-
tistics Aus-
tria, 2004) 
stage of 
devel-
opment
Is the technology 
already approved 
for other indica-
tions (incl. Or-
phan drug 
status) or by the 
FDA? 
costs in €
NA = not 
available 
COMMENTS
Expert 1 
COMMENTS 
Expert 2 
COMMENTS 
Expert 3 
Score 
E1 
Score 
E2 
Score 
E3 
Mean 
Score 
12 ARC 501 ArQule E2F1 Pathway Acti-vator 
monotherapy in 
head and neck 
cancer 
1.029 
(head and 
neck cancer)
Phase II No NA    0 1 3 1 
13 Aroplatin Antigenics 
third-generation 
platinum chemo-
therapeutic, lipo-
somal formulation 
colorectal cancer 
4.849  
(colorectal 
cancer) 
Phase II
FDA orphan drug 
designation for 
malignant meso-
thelioma 
NA    0 4 5 3 
14 Asentar (DN 101) Schering Plough 
high-dose oral for-
mulation of calcitriol, 
a potent hormone 
that exerts its effects 
through the vitamin 
D receptor (VDR) 
in combination 
with Taxotere for 
Prostate cancer 
5.416 
(prostate 
cancer, ma-
lignant) 
Phase III No NA    0 10 5 5 
15 Axitinib Pfizer 
VEGF-Tyrosinkinase-
Inhibitor, angiogene-
sis- inhibitor 
second-line treat-
ment of patients 
with metastatic 
colorectal cancer 
4.849  
(colorectal 
cancer) 
Phase II
FDA orphan drug 
designation for 
pancreatic cancer 
in July 2007 
NA    0 13 4 6 
 Axitinib Pfizer 
VEGF-Tyrosinkinase-
Inhibitor, angiogene-
sis- inhibitor 
advanced pancre-
atic cancer 
1.388 
(pancreatic 
cancer) 
Phase 
II/III 
FDA orphan drug 
designation for 
pancreatic cancer 
in July 2007 
NA    0 14 5 6 
 Axitinib Pfizer 
VEGF-Tyrosinkinase-
Inhibitor, angiogene-
sis- inhibitor 
Refractory Metas-
tatic Renal Cell 
Cancer 
1.224 
(kidney can-
cer) 
Phase II
FDA orphan drug 
designation for 
pancreatic cancer 
in July 2007 
NA  
bevacizumab 
already regis-
tered 
 0 5 3 3 
 Axitinib Pfizer 
VEGF-Tyrosinkinase-
Inhibitor, angiogene-
sis- inhibitor 
Advanced thyroid 
cancer 
686 
(thyroid can-
cer) 
Phase II
FDA orphan drug 
designation for 
pancreatic cancer 
in July 2007 
NA    0 4 4 3 
16 AZD0530 Astra Zeneca 
orally available, dual-
specific, Src/Abl 
kinase inhibitor 
advanced ovarian 
cancer 
783 
(ovarian can-
cer) 
Phase II No NA    0 8 2 3 
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No. Drug name (brand name) 
Company / De-
veloper 
Short Drug descrip-
tion 
Patients’ indica-
tions 
Number of 
patients with 
disease in 
Austria 
(Source: Sta-
tistics Aus-
tria, 2004) 
stage of 
devel-
opment
Is the technology 
already approved 
for other indica-
tions (incl. Or-
phan drug 
status) or by the 
FDA? 
costs in €
NA = not 
available 
COMMENTS
Expert 1 
COMMENTS 
Expert 2 
COMMENTS 
Expert 3 
Score 
E1 
Score 
E2 
Score 
E3 
Mean 
Score 
17 AZD2281 Astra Zeneca PARP inhibitor breast cancer 
4832 
(breast can-
cer in 
women) 
Phase II
EMEA orphan 
drug status for 
ovarian cancer in 
Dec 2007 
NA    0 15 3 6 
18 
AZD6244 
(ARRY-
142886) 
Astra Zeneca MEK inhibitor 
Unresectable AJCC 
Stage 3 or 4 Ma-
lignant Melanoma
1.169  
(malignant 
melanoma)
Phase II No NA    0 11 4 5 
19 Bavituximab Peregrine Phar-maceuticals monoclonal antibody
advanced breast 
cancer, combina-
tion with do-
cetaxel 
4832 
(breast can-
cer in 
women) 
Phase II No NA    0 1 3 1 
20 bendamustine (Treanda) Cephalon alkylating drug 
relapsed indolent 
Non-Hodgkin's 
Lymphoma - pro-
gress after/during 
rituximab regime
979 
(Non-
Hodgkin 
lymphoma)
Phase II
Extension of in-
dication; FDA 
approval for CLL 
in March 2008; 
approved in 
Germany 
Ribomustin 
25mg: 50€  
Bendamustine
works in mul-
tiple indica-
tions CLL, 
Myeloma al-
ready avail-
able 
data pre-
sented on 
ASH 07 
5 5 4 5 
21 Bevacizumab (Avastin) Genentech anti-VEGF antibody ovarian cancer 
783 
(ovarian can-
cer) 
Phase II
Extension of in-
dication; EMEA 
approval for 
breast cancer, 
CRC, NSCLC, RCC 
Avastin 
400mg: 
1300€ 
   11 11 4 9 
 Bevacizumab (Avastin) Genentech anti-VEGF antibody
in combination 
with erlotinib in 
advanced or me-
tastatic liver can-
cer 
872  
(liver cancer) Phase II
Extension of in-
dication 
Avastin 
400mg: 
1300€ 
   9 5 5 6 
 Bevacizumab (Avastin) Genentech anti-VEGF antibody
relapsed glioblas-
toma multiforme 
(GBM) 
638 
(all brain and 
CNS tu-
mours) 
Phase 
II/III 
Extension of in-
dication 
Avastin 
400mg: 
1300€ 
   8 11 6 8 
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No. Drug name (brand name) 
Company / De-
veloper 
Short Drug descrip-
tion 
Patients’ indica-
tions 
Number of 
patients with 
disease in 
Austria 
(Source: Sta-
tistics Aus-
tria, 2004) 
stage of 
devel-
opment
Is the technology 
already approved 
for other indica-
tions (incl. Or-
phan drug 
status) or by the 
FDA? 
costs in €
NA = not 
available 
COMMENTS
Expert 1 
COMMENTS 
Expert 2 
COMMENTS 
Expert 3 
Score 
E1 
Score 
E2 
Score 
E3 
Mean 
Score 
22 Bexarotene (Targretin) Cephalon 
inhibition of Reti-
noid-X-Receptors, 
synthetic retinoid, 
orally 
in Chemotherapy-
Naive Patients 
With Advanced or 
Metastatic Non-
Small-Cell Lung 
Cancer,  in combi-
nation with cis-
platin and vinorel-
bine 
3.864 
(lung cancer, 
all forms) 
Phase III
EMEA approval 
for cutanous T-
cell lymphoma 
since 2001 
Targretin 
75mg 100 
Kps: 1780€
   8 3 6 6 
23 BIBW 2992* Boehringer Ingelheim 
dual EGFR/HER2 
(ErbB2) tyrosine 
kinase inhibitor, sec-
ond generation 
NSCLC (late stage)
3.864 
(lung cancer, 
all forms) 
Phase III
Fast Track Des-
ignation status 
by the FDA in 
Feb 2008 
NA    10 14 5 10 
24 Brivanib (BMS-582664 
Bristol-Meyers-
Squibb 
vascular endothelial 
growth factor recep-
tor 2 (VEGFR2) in-
hibitor 
metastatic colo-
rectal cancer 
4.849  
(colorectal 
cancer) 
Phase 
II/III No NA  
multiple al-
ternatives  12 6 4 7 
25 Brostallicin Cell Therapeutics 
a synthetic DNA mi-
nor groove binding 
agent 
first-line single-
agent chemother-
apy in patients 
with advanced or 
metastatic soft tis-
sue sarcoma 
NA Phase II No NA    0 1 4 2 
26 
CC-4047 (po-
malidomide / 
actimid) 
Celegene thalidomide ana-logue 
metastatic hor-
mone refractory 
prostate cancer 
(HRPC) 
5.416 
(prostate 
cancer, ma-
lignant) 
Phase II No NA    10 10 3 8 
27 CDX-110 Celldex Thera-peutics 
a EGFRvIII Vaccine, 
Immunotherapy 
Radiation and Te-
mozolomide in Pa-
tients with Newly 
Diagnosed 
Glioblastoma Mul-
tiforme 
638 
(all brain and 
CNS tu-
mours) 
Phase 
II/III 
FDA orphan drug 
status for 
glioblastoma 
multiforme in 
Dec 2007 
NA    7 9 4 7 
28 Cediranib (Re-centin) Astra Zeneca 
oral VEGFR-
Tyrosinkinase-
Inhibitor 
metastatic colo-
rectal cancer 
4.849  
(colorectal 
cancer) 
Phase III No NA    9 8 4 7 
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No. Drug name (brand name) 
Company / De-
veloper 
Short Drug descrip-
tion 
Patients’ indica-
tions 
Number of 
patients with 
disease in 
Austria 
(Source: Sta-
tistics Aus-
tria, 2004) 
stage of 
devel-
opment
Is the technology 
already approved 
for other indica-
tions (incl. Or-
phan drug 
status) or by the 
FDA? 
costs in €
NA = not 
available 
COMMENTS
Expert 1 
COMMENTS 
Expert 2 
COMMENTS 
Expert 3 
Score 
E1 
Score 
E2 
Score 
E3 
Mean 
Score 
29 Lestaurtinib (CEP-701) Cephalon 
receptor tyrosine 
kinase inhibitor AML 
964  
(leukaemia, 
all forms) 
Phase II
FDA orphan drug 
status for AML in 
April 2006 and 
EMEA orphan 
drug in 2006 
NA    0 8 3 4 
30 Cetuximab (Er-bitux) Merck 
in combination with 
gemcitabine and cis-
platin 
advanced pancre-
atic cancer 
1.388 
(pancreatic 
cancer) 
Phase II
Extension of in-
dication; ap-
proved for colo-
rectal cancer and 
head and neck 
cancer by EMEA 
Erbitux 
100mg: 
220€ 
   11 10 6 9 
 Cetuximab* (Erbitux) Merck 
in combination with 
cisplatin/vinorelbine
first-line therapy 
in EGFR-
expressing ad-
vanced non-small-
cell lung cancer 
3.864 
(lung cancer, 
all forms) 
Phase II
Extension of in-
dication; ap-
proved for colo-
rectal cancer and 
head and neck 
cancer by EMEA 
Erbitux 
100mg: 
220€ 
   12 11 6 10 
31 Cloretazine Vion Pharma-ceuticals alkylating drug 
relapsed AML, in 
combination with 
cytarabine 
964  
(leukaemia, 
all forms) 
Phase III FDA orphan drug status since 2005 NA    4 3 4 4 
32 Tremelimumab (CP-675206) Pfizer 
CTLA4-rezeptor An-
tagonist Melanoma 
1.169  
(malignant 
melanoma)
Phase III No NA    7 10 3 7 
33 Darinaparsin Ziopharma a new class of or-ganic arsenicals 
advanced mye-
loma NA Phase II No NA    0 3 3 2 
34 DCVax Northwest Bio-therapeutics brain cancer vaccine
Glioblastoma mul-
tiforme 
638 
(all brain and 
CNS tu-
mours) 
Phase II
approved in 
Switzerland since 
Sept 2007 
NA    0 9 5 5 
35 Deforolimus Merck 
Inhibitor of 
mTOR(mammalian 
Target of Rapamy-
cin)-Kinase 
metastatic soft-
tissue and bone 
sarcomas 
NA Phase III No NA    8 6 7 7 
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No. Drug name (brand name) 
Company / De-
veloper 
Short Drug descrip-
tion 
Patients’ indica-
tions 
Number of 
patients with 
disease in 
Austria 
(Source: Sta-
tistics Aus-
tria, 2004) 
stage of 
devel-
opment
Is the technology 
already approved 
for other indica-
tions (incl. Or-
phan drug 
status) or by the 
FDA? 
costs in €
NA = not 
available 
COMMENTS
Expert 1 
COMMENTS 
Expert 2 
COMMENTS 
Expert 3 
Score 
E1 
Score 
E2 
Score 
E3 
Mean 
Score 
36 Degarelix (Fir-magon) Ferring 
GnRH blocker, an-
drogen deprivation 
therapy 
advanced prostate 
cancer 
5.416 
(prostate 
cancer, ma-
lignant) 
Phase III No NA  me too drug  9 7 5 7 
37 Denosumab Amgen 
human monoclonal 
antibody, targets the 
receptor activator of 
nuclear factor kappa 
B ligand (“RANKL”),
multiple myeloma NA Phase II No NA  
drug is in 
phase 3 -> 
supportive 
therapy alter-
native to 
bisphopho-
nates 
 0 11 5 5 
 Denosumab* Amgen 
human monoclonal 
antibody, targets the 
receptor activator of 
nuclear factor kappa 
B ligand (“RANKL”),
Prostate cancer 
5.416 
(prostate 
cancer, ma-
lignant) 
Phase III No NA  
drug is in 
phase 3 -> 
supportive 
therapy alter-
native to 
bisphopho-
nates 
 13 13 5 10 
38 E10A Double Biopro-duct Inc 
Adenovirus-Mediated 
Endostatin Gene 
(E10A) 
head and neck 
cancer 
1.029 
(head and 
neck cancer)
Phase II No NA    0 4 3 2 
39 Eribulin (E7389) Eisai 
synthetic analogue 
of halichondrin B 
(HB), 
third-line treat-
ment of advanced 
breast cancer in 
patients who were 
pre-treated with 
anthracycline, tax-
ane and capecit-
abine 
4.832 
(breast can-
cer in 
women) 
Phase III No NA    12 4 2 6 
40 Edotecarin Pfizer topoisomerase in-hibitor 
Glioblastoma mul-
tiforme 
638 
(all brain and 
CNS tu-
mours) 
Phase III No NA    6 8 6 7 
41 Elacyt Clavis 
elaidic acid ester of 
the antimetabolite 
cytarabine 
first line, single 
agent therapy in 
metastatic malig-
nant melanoma 
1.169  
(malignant 
melanoma)
Phase II No NA    0 5 3 3 
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No. Drug name (brand name) 
Company / De-
veloper 
Short Drug descrip-
tion 
Patients’ indica-
tions 
Number of 
patients with 
disease in 
Austria 
(Source: Sta-
tistics Aus-
tria, 2004) 
stage of 
devel-
opment
Is the technology 
already approved 
for other indica-
tions (incl. Or-
phan drug 
status) or by the 
FDA? 
costs in €
NA = not 
available 
COMMENTS
Expert 1 
COMMENTS 
Expert 2 
COMMENTS 
Expert 3 
Score 
E1 
Score 
E2 
Score 
E3 
Mean 
Score 
42 Elesclomol 
Synta Pharma-
ceuticals and 
GSK 
increase in oxidative 
stress – the level of 
reactive oxygen spe-
cies (ROS), novel 
mechanism 
stage IV metas-
tatic melanoma 
1.169  
(malignant 
melanoma)
Phase III
FDA orphan drug 
status for mela-
noma in Jan 
2008 
NA    7 11 3 7 
43 EndoTAG-1 Medigene in combination with gemcitabine 
in pancreatic can-
cer 
1.388 
(pancreatic 
cancer) 
Phase II No NA    0 6 3 3 
44 Enzastaurin Lilly oral serine/threonine kinase inhibitor 
Second or Third 
line Therapy of 
NSCLC 
3.864 
(lung cancer, 
all forms) 
Phase II No NA    1 8 3 4 
45 Everolimus Novartis serine/threonine kinase inhibitor 
advanced kidney 
cancer 
1.224 
(kidney can-
cer) 
Phase III
EMEA orphan 
drug status for 
kidney cancer in 
June 2007 
NA    6 10 5 7 
46 Forodesine BioCryst Phar-maceuticals 
purine nucleoside 
phosphorylase (PNP) 
inhibitor 
CLL 
964  
(leukaemia, 
all forms) 
Phase II No NA    0 3 1 1 
47 GDC-0449 Genentech Hedgehog antagonist
First-line therapy 
for metastatic co-
lorectal cancer 
4.849  
(colorectal 
cancer) 
Phase II No NA    0 10 3 4 
48 Gefitinib (Ir-essa) Astra Zeneca 
tyrosinkinase inhibi-
tor, orally 
first-line in ad-
vanced colorectal 
cancer (combina-
tion with FOLFOX-
4) 
4.849  
(colorectal 
cancer) 
Phase II
FDA approval for 
NSCLC since 
2003 
NA   
data pre-
sented on 
ASCO 08 
10 5 4 6 
 Gefitinib (Ir-essa) Astra Zeneca 
tyrosinkinase inhibi-
tor, orally 
first-line therapy 
followed by che-
motherapy in ad-
vanced non-small-
cell lung cancer 
3.864 
(lung cancer, 
all forms) 
Phase II
FDA approval for 
NSCLC since 
2004 
NA    10 5 3 6 
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No. Drug name (brand name) 
Company / De-
veloper 
Short Drug descrip-
tion 
Patients’ indica-
tions 
Number of 
patients with 
disease in 
Austria 
(Source: Sta-
tistics Aus-
tria, 2004) 
stage of 
devel-
opment
Is the technology 
already approved 
for other indica-
tions (incl. Or-
phan drug 
status) or by the 
FDA? 
costs in €
NA = not 
available 
COMMENTS
Expert 1 
COMMENTS 
Expert 2 
COMMENTS 
Expert 3 
Score 
E1 
Score 
E2 
Score 
E3 
Mean 
Score 
49 
gemtuzumab 
ozogamicin 
(Mylotarg) 
Wyeth CD33 monoclonal an-tibody 
added to fludara-
bine, melphalan 
and allergenic 
haematopoietic 
stem cell trans-
plantation for 
high-risk CD33 
positive myeloid 
leukaemia and 
myelodysplastic 
syndrome 
964  
(leukaemia, 
all forms) 
Phase 
I/II 
EMEA recom-
mended refusal 
of marketing au-
thorisation for 
AML in Jan 2008 
NA  
only in very 
specialized 
centres used 
 0 6 1 2 
50 GI-4000 Tar-mogen GlobeImmune 
causes the targeted 
elimination of any 
cell containing muta-
tions in the ras  on-
cogene 
NSCLC 
3.864 
(lung cancer, 
all forms) 
Phase IIa No NA    0 10 2 4 
51 Glufosfamide Treshold Phar-maceuticals alkylating drug 
soft tissue sar-
coma NA Phase II
FDA orphan drug 
status for pan-
creatic cancer in 
Sept 2006 
NA    0 4 4 3 
 Glufosfamide Treshold Phar-maceuticals alkylating drug 
platinum-resistant 
ovarian cancer 
783 
(ovarian can-
cer) 
Phase II
FDA orphan drug 
status for pan-
creatic cancer in 
Sept 2007 
NA    0 6 2 3 
52 GVAX Cell Genesys Immunotherapy Prostate cancer 
5.416 
(prostate 
cancer, ma-
lignant) 
Phase III FDA Fast track status NA    0 8 4 4 
53 Hu3S193 NA Y90 - monoclonal an-tibody 
ovarian epithelial 
cancer, fallopian 
tube cancer, or 
peritoneal cavity 
cancer 
783 
(ovarian can-
cer) 
Phase II No NA    0 4 3 2 
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No. Drug name (brand name) 
Company / De-
veloper 
Short Drug descrip-
tion 
Patients’ indica-
tions 
Number of 
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54 huC242-DM4 ImmunoGen 
immunotoxin of a 
humanized mono-
clonal antibody C242 
(MoAb HuC242) con-
jugated with a de-
rivative of cytotoxic 
agent maytansine, 
DM4 
metastatic or lo-
cally advanced 
gastric or gastroe-
sophageal junction 
cancer 
1.442 
(gastric can-
cer) 
Phase II No NA    0 4 3 2 
55 Imatinib (Glivec) Novartis 
protein-tyrosine 
kinase inhibitor, 
orally 
Unresectable 
Hepatocellular 
Carcinoma 
872  
(liver cancer) Phase II
Extension of in-
dication; EMEA 
approval for 
other indications 
NA  alternatives negative re-sults known 7 4 1 4 
56 IMC-1121B ImClone 
an anti-vascular en-
dothelial growth fac-
tor receptor-2 
(VEGFR-2) mono-
clonal antibody 
liver cancer 872  (liver cancer) Phase II No NA  alternatives  0 4 2 2 
57 IMC-11F8 ImClone against EGFR advanced colorec-tal cancer 
4.849  
(colorectal 
cancer) 
Phase II No NA  alternatives  0 6 2 3 
58 IMC-A12 ImClone 
anti-IGF-1R recombi-
nant monoclonal an-
tibody 
metastatic pancre-
atic cancer 
1.388 
(pancreatic 
cancer) 
Phase II No NA    0 10 3 4 
 IMC-A12 ImClone 
anti-IGF-1R recombi-
nant monoclonal an-
tibody 
advanced liver 
cancer 
872  
(liver cancer) Phase II No NA    0 9 3 4 
59 IPI-504 Medimmune 
A small-molecule in-
hibitor of heat shock 
protein 90 (HSP90) 
with antiproliferative 
and antineoplastic 
activities, IPI-504 
binds to and inhibits 
the cytosolic chaper-
one functions of 
HSP90 
advanced breast 
cancer 
4.832 
(breast can-
cer in 
women) 
Phase II
FDA granted or-
phan drug desig-
nation for the 
treatment of 
gastrointestinal 
stromal tumors 
(GISTs) in August 
2007 
NA    0 9 1 3 
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60 Ipilimumab Bristol-Meyers-Squibb 
monoclonal antibody 
directed against cy-
totoxic T-
lymphocyte-
associated antigen-4 
(CTLA4 
with dacarbazine 
as a first-line ther-
apy for metastatic 
melanoma or as 
monotherapy for 
second-line ther-
apy for metastatic 
melanoma 
1.169  
(malignant 
melanoma)
Phase II
Fast Track Des-
ignation status 
by the FDA in 
Feb 2007 
NA    0 12 3 5 
61 Ispinesib (SB-715992) Cytokines 
a novel kinesin spin-
dle protein inhibitor
metastatic breast 
cancer 
4.832 
(breast can-
cer in 
women) 
Phase II No NA    0 12 2 5 
62 Ixabepilone (Ixempra) 
Bristol-Meyers-
Squibb 
a microtubule inhibi-
tor belonging to a 
class of antineoplas-
tic agents, the 
epothilones 
in combination 
with capecitabine 
for the treatment 
of patients with 
metastatic or lo-
cally advanced 
breast cancer re-
sistant to treat-
ment with an an-
thracycline, and a 
taxane 
4.832 
(breast can-
cer in 
women) 
Phase II
FDA approval for 
breast cancer in 
Oct 2007 
NA    10 11 2 8 
63 Karenitecin BioNumerik Pharmaceuticals 
member of the camp-
tothecin class, camp-
tothecin related 
advanced ovarian 
cancer, resistant to 
platinum and tax-
ane chemotherapy 
drugs 
783 
(ovarian can-
cer) 
Phase III No NA    10 9 4 8 
64 larotaxel (XRP9881) Sanofi-Aventis 
in combination with 
cisplatin 
first line treatment 
of locally ad-
vanced/metastatic 
urothelial tract or 
bladder cancer 
1.705 
(bladder can-
cer) 
Phase III No NA    4 10 4 6 
65 Lumiliximab Biogen 
a monoclonal anti-
body targeted 
against the CD23 an-
tigen 
CLL 
964  
(leukaemia, 
all forms) 
Phase 
II/III 
Orphan drug - 
EMEA positive 
opinion - Jan 
2008, FDA or-
phan drug status 
NA  
might be ef-
fective in lot 
of lymphomas
 7 12 3 7 
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66 Volociximab (M200) Biogen 
anti-angiogenic α5β1 
integrin inhibitor 
ovarian cancer or 
primary peritoneal 
cancer, in combi-
nation with 
doxorubicin 
783 
(ovarian can-
cer) 
Phase II No NA    0 10 2 4 
67 MGCD0103 Pharmion 
histone deacetylase 
inhibitor, orally-
administered, iso-
type-selective HDAC 
inhibitor 
AML 
964  
(leukaemia, 
all forms) 
Phase II
EMEA orphan 
drug status for 
the treatment of 
Hodgkin lym-
phoma and for 
AML 2008,FDA 
orphan drug 
status in Sept 
2007 
NA  might work in MDS  0 11 2 4 
68 mifamurtide (L-MTP-PE) IDM Pharma 
a lipophilic derivative 
of the muramyl 
dipeptide 
non-metastatic, 
resectable os-
teosarcoma 
NA Phase III
EMEA orphan 
drug status in 
2004, FDA or-
phan drug  
NA    7 7 6 7 
69 Milatuzumab Immunomedici-nes 
humanized anti-
CD74 antibody multiple myeloma NA Phase II
FDA orphan drug 
designation in 
March 2008 
NA    7 11 5 8 
70 MK0646 Merck 
Insulin-Like Growth 
Factor Receptor In-
hibitor 
metastatic colo-
rectal cancer, in 
combination with 
cetuximab and iri-
notecan 
4.849  
(colorectal 
cancer) 
Phase II No NA    12 6 3 7 
71 Motesanib* Amgen Multikinase-Inhibitor First-line for NSCLC 
3.864 
(lung cancer, 
all forms) 
Phase III No NA    11 14 5 10 
 Motesanib Amgen Multikinase-Inhibitor Thyroid cancer 
686 
(thyroid can-
cer) 
Phase II No NA    9 10 5 8 
 Motesanib Amgen Multikinase-Inhibitor first-line breast cancer 
4.832 
(breast can-
cer in 
women) 
Phase II No NA    11 14 3 9 
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72 Naptumomab estafenatox 
Active Biotech 
Research 
a fusion protein con-
sisting of one antigen 
binding fragment 
(Fab) from a cancer 
cell binding antibody 
and a bacterial super-
antigen 
renal cell carci-
noma 
1.224 
(kidney can-
cer) 
Phase II
Orphan drug - 
EMEA positive 
opinion in Dec 
2007 
NA    7 7 2 5 
73 
NKTR-102 
(PEG-
Irinotecan) 
Nektar Thera-
peutics 
PEGylated form of ir-
inotecan colorectal cancer 
4.849  
(colorectal 
cancer) 
Phase II new formulation of irinotecan NA    11 7 1 6 
74 Oblimersen (Genasense) Genta 
bcl-2 Antisense Oli-
gonucleotide 
Oblimersen 
initial therapy for 
extensive-stage 
small-cell lung 
cancer (ES-SCLC 
3.864 
(lung cancer, 
all forms) 
Phase II No NA    10 13 5 9 
 Oblimersen (Genasense) Genta 
bcl-2 Antisense Oli-
gonucleotide 
Oblimersen 
relapsed or refrac-
tory CLL 
964  
(leukaemia, 
all forms) 
Phase II No NA  
might be ef-
fective in lot 
of lymphomas
 9 12 1 7 
75 Ofatumumab Genmab human monoclonal anti-CD20 antibody
relapsed or refrac-
tory CLL 
964  
(leukaemia, 
all forms) 
Phase 
I/II No NA  
might be ef-
fective in lot 
of lymphomas
 4 12 2 6 
76 OGX-011 (custirsen) OncoGenex 
is designed to block 
production of clus-
terin, a cell survival 
protein that is over-
produced in several 
cancer indications 
second-line che-
motherapy in pa-
tients with hor-
mone refractory 
prostate cancer 
5.416 
(prostate 
cancer, ma-
lignant) 
Phase II No NA    9 12 3 8 
77 Vitespen (On-cophage) Antigenics 
autologous, tumour- 
derived heat shock 
protein gp96 peptide 
complexes, cancer 
vaccine 
kidney cancer 
1.224 
(kidney can-
cer) 
Phase 
II/III 
EMEA orphan 
drug status NA    8 10 3 7 
 vitespen (On-cophage) Antigenics 
autologous, tumour- 
derived heat shock 
protein gp96 peptide 
complexes, cancer 
vaccine 
stage IV mela-
noma 
1.169  
(malignant 
melanoma)
Phase 
II/III 
EMEA orphan 
drug status NA    8 10 3 7 
78 Ortataxel Indena a novel second-generation taxane 
taxane-resistant 
NSCLC 
3.864 
(lung cancer, 
all forms) 
Phase II No NA    8 8 5 7 
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79 
Paclitaxel 
poliglumex, 
CT-2103 (Xyo-
tax) 
Cell Therapeutics 
large macromolecule 
conjugate of pacli-
taxel 
first-line therapy 
in NSCLC 
3.864 
(lung cancer, 
all forms) 
Phase III
new formulation 
of paclitaxel, in 
approval by 
EMEA 
NA    11 8 5 8 
80 Palifosfamide Ziopharma stabilized metabolite of ifosfamide 
in combination 
with  doxorubicin 
in the treatment 
of patients with 
sarcoma 
NA Phase II No NA    7 3 4 5 
81 Panitumumab (vectibix) Amgen 
EGFR monoclonal 
antibody 
head and neck 
cancer 
1.029 
(head and 
neck cancer)
Phase 
II/III 
EMEA approval 
for colorectal 
cancer in 2007 
NA 
Initially for 
patients 
with recur-
rent cancer, 
extension of 
indication 
possible (see
Cetuximab)
me too for 
cetuximab  9 10 7 9 
82 panobinostat Novartis 
a member of the hy-
droxamic acid group 
of histone deacety-
lase (HDAC) inhibi-
tors 
cutanes T-cell lym-
phoma, topical 
treatment 
NA Phase II/III 
Orphan drug - 
EMEA positive 
opinion in Au-
gust 2007, FDA 
orphan drug in 
Sept 2007 
NA    1 3 5 3 
83 Panzem NCD EntreMed Inc. 
blocking the VEGF 
receptor and by in-
hibiting HIF-1alpha,
advanced or me-
tastatic carcinoid 
tumours, in com-
bination with 
bevacizumab 
NA Phase II No NA  me too  6 2 1 3 
84 pazopanib (Ar-mala) GSK 
multi kinase angio-
genesis inhibitor renal cell cancer 
1.224 
(kidney can-
cer) 
Phase III EMEA orphan drug status 2006 NA  
several alter-
natives  10 8 2 7 
85 pralatrexate Allos Therapeu-tics 
novel, next-
generation small 
molecule chemo-
therapeutic agent 
that inhibits dihydro-
folate reductase 
relapsed or refrac-
tory peripheral T-
cell lymphoma 
1.130  
(lymphoma, 
all forms) 
Phase II 
(PROPEL 
Trial) 
No NA    8 5 5 6 
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 pralatrexate Allos Therapeu-tics 
novel, next-
generation small 
molecule chemo-
therapeutic agent 
that inhibits dihydro-
folate reductase 
stage IIIB/IV 
NSCLC (failed 
prior platinum-
based regime); 
comparison to er-
lotinib (tarceva) 
3.864 
(lung cancer, 
all forms) 
Phase IIb No NA    8 12 1 7 
86 Perifosine Aetrena Zentaris 
An orally active al-
kyl-phosphocholine 
compound, inhibits 
the anti-apoptotic 
mitogen-activated 
protein kinase 
(MAPK) pathway 
NSCLC 
3.864 
(lung cancer, 
all forms) 
Phase II No NA    11 10 1 7 
87 Pertuzumab (Omnitarg) Roche 
blocks the human 
epidermal growth 
factor (HER) recep-
tor family, 
advanced HER2-
positive breast 
cancer,  in combi-
nation with Tras-
tuzumab 
4.832 
(breast can-
cer in 
women) 
Phase 
II/III No NA  
might replace 
Herceptin  11 11 4 9 
88 Phenoxodiol Marshall Ed-wards, Inc 
regulates signal 
transduction path-
ways in cancer cells 
resulting in the break 
down of the intra-
cellular proteins -- 
XIAP (X-linked In-
hibitor of Apoptosis 
Protein) and FLIP 
(Fas Ligand Inhibi-
tory Protein) 
platinum resistant 
ovarian cancer 
783 
(ovarian can-
cer) 
Phase III FDA Fast track status NA    11 11 2 8 
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89 PI-88 PROGEN Phar-maceuticals 
Heparanase inhibitor 
PI-88 inhibits the 
endo-beta-D-
glucuronidase 
heparanase, which 
may interfere with 
the heparanase-
mediated degrada-
tion of heparan-
sulfate proteoglycans 
in extracellular ma-
trices, an important 
step in the metas-
tatic process 
hepatocellular car-
cinoma 
872  
(liver cancer)
Phase 
II/III No NA    6 4 2 4 
 PI-88 PROGEN Phar-maceuticals 
Heparanase inhibitor 
PI-88 inhibits the 
endo-beta-D-
glucuronidase 
heparanase, which 
may interfere with 
the heparanase-
mediated degrada-
tion of heparan-
sulfate proteoglycans 
in extracellular ma-
trices, an important 
step in the metas-
tatic process 
combination with 
docetaxel in pros-
tate cancer 
5.416 
(prostate 
cancer, ma-
lignant) 
Phase II No NA    9 6 3 6 
90 picoplatin Poniard Pharma-ceuticals 
new generation or-
ganic platinum ana-
logue 
small-cell lung 
cancer (SCLC) 
3.864 
(lung cancer, 
all forms) 
Phase 
II/III 
Orphan drug - 
EMEA positive 
opinion 2007 for 
SCLC 
NA    8 11 4 8 
91 pixantrone Cell Therapeutics novel anthracycline derivate 
non-Hodgkin 
Lymphoma (NHL)
979 
(Non-
Hodgkin 
lymphoma)
Phase III FDA Fast track status NA    5 8 2 5 
92 Provenge (Sip-uleucel-T) Dendreon 
cellular immunother-
apy 
advanced prostate 
cancer 
5.416 
(prostate 
cancer, ma-
lignant) 
Phase III FDA approval 2007 NA 
no FDA ap-
proval 2007 
– was with-
drawn 
  11 13 3 9 
93 RAV12 Raven Biotech- monoclonal antibody metastatic pancre- 1.388 Phase II No NA    12 10 4 9 
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nology atic cancer, in 
combination with 
gemcitabine 
(pancreatic 
cancer) 
94 Reolysin Oncolytics Bio-tech 
a novel treatment for 
Ras activated tumour 
cells 
metastatic ovar-
ian, peritoneal or 
fallopian tube can-
cer 
783 
(ovarian can-
cer) 
Phase 
I/II No NA    6 5 3 5 
95 RP101 SciClone nucleoside analogue
adjunct treatment 
of pancreatic can-
cer, in combina-
tion with gemcit-
abine 
1.388 
(pancreatic 
cancer) 
Phase II
FDA orphan drug 
designation in 
Feb 2008 
NA    7 7 3 6 
96 S-1 Taiho Pharma-ceuticals 
orally active combi-
nation of tegafur, 
gimeracil (an inhibi-
tor of dihydro-
pyrimidine dehydro-
genase, which de-
grades fluorouracil), 
and oteracil (which 
inhibits the phos-
phorylation of 
fluorouracil in the GI 
tract) 
first-line treat-
ment of advanced 
gastric cancer 
1.442 
(gastric can-
cer) 
Phase III No NA    9 5 3 6 
97 Sarasar Schering Plough Farnesyl transferase inhibitor breast cancer 
4.832 
(breast can-
cer in 
women) 
Phase 
II/III No NA    4 9 2 5 
98 SNDX-275 Syndax 
HDAC inhibitor 
SNDX-275 binds to 
and inhibits histone 
deacetylase, an en-
zyme that regulates 
chromatin structure 
and gene transcrip-
tion 
in combination 
with erlotinib in 
the treatment of 
Advanced Non-
Small Cell Lung 
Cancer 
3.864 
(lung cancer, 
all forms) 
Phase II No NA    7 13 1 7 
99 SNS-595 Sunesis Pharma-ceuticals 
topoisomerase II in-
hibitor 
in platinum-
resistant ovarian 
cancer patients 
783 
(ovarian can-
cer) 
Phase II No NA    4 4 2 3 
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100 Sorafenib (Nexavar) Bayer Schering 
tyrosinkinase inhibi-
tor, orally AML 
964  
(leukaemia, 
all forms) 
Phase II
Extension of in-
dication; EMEA 
approval for HCC 
and RCC 
Nexavar 
200mg 
Tabl 112 St: 
3800€ 
   7 7 7 7 
 Sorafenib (Nexavar) Bayer Schering 
tyrosinkinase inhibi-
tor, orally breast cancer 
4.832 
(breast can-
cer in 
women) 
Phase II
Extension of in-
dication EMEA 
approval for HCC 
and RCC 
Nexavar 
200mg 
Tabl 112 St: 
3800€ 
   10 12 5 9 
 Sorafenib (Nexavar) Bayer Schering 
tyrosinkinase inhibi-
tor, orally 
first line for mela-
noma 
1.169  
(malignant 
melanoma)
Phase III
Extension of in-
dication, EMEA 
approval for HCC 
and RCC 
Nexavar 
200mg 
Tabl 112 St: 
3800€ 
  
negative re-
sults Phase 
III known 
10 8 3 7 
 Sorafenib (Nexavar) Bayer Schering 
tyrosinkinase inhibi-
tor, orally 
First-line for 
NSCLC 
3.864 
(lung cancer, 
all forms) 
Phase III
Extension of in-
dication, EMEA 
approval for HCC 
and RCC 
Nexavar 
200mg 
Tabl 112 St: 
3800€ 
   12 12 4 9 
 Sorafenib (Nexavar) Bayer Schering 
tyrosinkinase inhibi-
tor, orally 
chemo-naive cas-
tration-resistant 
prostate cancer 
5.416 
(prostate 
cancer, ma-
lignant) 
Phase II
Extension of in-
dication, EMEA 
approval for HCC 
and RCC 
Nexavar 
200mg 
Tabl 112 St: 
3800€ 
   12 12 2 9 
101 Sunitinib (Sutent) Pfizer 
tyrosinkinase inhibi-
tor, orally 
previously treated 
advanced NSCLC 
3.864 
(lung cancer, 
all forms) 
Phase II
Extension of in-
dication, EMEA 
approval for GIST 
and RCC 
Sutent 25 
mg Kps 30 
St: 2600€
   12 12 4 9 
 Sunitinib (Sutent) Pfizer 
tyrosinkinase inhibi-
tor, orally 
Metastatic Breast 
Cancer Previously 
Treated With an 
Anthracycline and 
a Taxane 
4.832 
(breast can-
cer in 
women) 
Phase II
Extension of in-
dication, EMEA 
approval for GIST 
and RCC 
Sutent 25 
mg Kps 30 
St: 2600€
   10 12 4 9 
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102 Tanespimycin Kosan Biosci-ences 
binds to and inhibits 
the cytosolic chaper-
one functions of heat 
shock protein 90 
(HSP90) 
multiple myeloma  
(after first relapse, 
in combination 
with bortezomib - 
Velcade) 
NA 
Phase III 
(TIME-1 
trial) 
No NA    10 12 6 9 
103 Tesetaxel Genta oral formulation, semisynthetic taxane NSCLC 
3.864 
(lung cancer, 
all forms) 
Phase II No NA    13 7 4 8 
104 TG4010 Vac-cine Transgene cancer vaccine 
as adjunct in first-
line chemotherapy 
of NSCLC (combi-
nation with cis-
platin + gemcit-
abine) 
3.864 
(lung cancer, 
all forms) 
Phase IIb No NA    9 7 1 6 
105 Thalidomide Pharmion in combination with topotecan 
recurrent ovarian 
cancer 
783 
(ovarian can-
cer) 
Phase II
EMEA orphan 
drug status for 
multiple mye-
loma 
NA    7 4 4 5 
106 Trilostane (Modrenal) Bioenvision 
A synthetic deriva-
tive of androstane 
with adrenocortical 
suppressive proper-
ties. Trilostane re-
versibly inhibits 3 
beta-hydroxysteroid 
dehydrogenase delta 
5-4 isomerase in the 
adrenal cortex, re-
sulting in the de-
creased synthesis of 
mineralocorticoids 
post-menopausal 
advanced breast 
cancer following 
relapse to initial 
hormone therapy
4.832 
(breast can-
cer in 
women) 
Phase II No NA    10 6 4 7 
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107 Triphendiol BioSpace 
down regulation of 
the expression of X-
linked inhibitor of 
apoptosis, oral sec-
ond-generation de-
rivative of 
phenoxodiol 
Stage IIB through 
Stage IV malignant 
melanoma 
1.169  
(malignant 
melanoma)
Phase 
II/III 
FDA orphan drug 
status in Feb 
2008; FDA Or-
phan Drug status 
for the treat-
ment of pancre-
atic cancer and 
for the treat-
ment of cholan-
gio-carcinoma 
NA    6 10 1 6 
108 TroVax Biomedica cancer immunother-apy renal cancer 
1.224 
(kidney can-
cer) 
Phase III No NA 
Studies on 
colorectal 
cancer exist, 
possible 
high costs 
due to high 
number of 
patients 
with disease
  10 6 3 6 
 TroVax Biomedica cancer immunother-apy 
metastatic hor-
mone-refractory 
prostate cancer 
5.416 
(prostate 
cancer, ma-
lignant) 
Phase II No NA    13 8 1 7 
109 Urocidin Bioniche 
Mycobacterial Cell 
Wall-DNA Complex 
(MCC) is formulated 
from Mycobacterium 
phlei, a non-
pathogenic strain of 
mycobacteria. MCC 
has been shown to 
have immune stimu-
latory and apoptosis 
(programmed cell 
death) activity 
against cancer cells 
first-line non-
muscle-invasive 
bladder cancer 
1.705 
(bladder can-
cer) 
Phase III FDA Fast track status NA    3 10 4 6 
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110 Vandetanib* (Zactima) Astra Zeneca 
VEGF/EGF TK inhibi-
tor with RET kinase 
activity 
for non-small cell 
lung cancer – lo-
cally advanced or 
metastatic, second 
line therapy 
3.864 
(lung cancer, 
all forms) 
Phase III
FDA and EMEA 
orphan drug 
status 
NA    10 15 5 10 
 Vandetanib (Zactima) Astra Zeneca 
VEGF/EGF TK inhibi-
tor with RET kinase 
activity 
Medullary thyroid 
cancer – locally 
advanced or me-
tastatic 
686 
(thyroid can-
cer) 
Phase II
FDA and EMEA 
orphan drug 
status 
NA    9 10 4 8 
111 VDQ-002 VioQuest inhibits protein kinase B multiple myeloma NA Phase II
FDA orphan drug 
designation in 
Feb 2008 
NA    9 12 1 7 
112 Veltuzumab Immunomedics 
humanised IgG1 
monoclonal anti-
CD22 antibody 
non-Hodgkin 
Lymphoma (NHL)
979 
(Non-
Hodgkin 
lymphoma)
Phase III No NA  several alter-natives  8 7 6 7 
113 Vorinostat (Zolinza) Merck 
A synthetic hydrox-
amic acid derivative 
with antineoplastic 
activity. Vorinostat, a 
second generation 
polar-planar com-
pound, binds to the 
catalytic domain of 
the histone deacety-
lases (HDACs). 
AML 
964  
(leukaemia, 
all forms) 
Phase 
II/III No NA 
Out-patient, 
FDA ap-
proval for 
cutanous T-
cell Lym-
phoma 
  7 8 4 6 
114 WX-671 Wilex AG 
an oral second gen-
eration serine prote-
ase inhibitor 
HER2-receptor 
negative metas-
tatic breast cancer, 
in combination 
with capecitabine
4.832 
(breast can-
cer in 
women) 
Phase II No NA 
Oral = no 
impact on 
hospital 
budget 
  11 6 2 6 
115 XL-184 Exelixis multi-tyrosine kinase inhibitor 
NSCLC (progres-
sive disease while 
on erlotinib ther-
apy) 
3.864 
(lung cancer, 
all forms) 
Phase 
I/II No NA    13 11 1 8 
116 ZD4054 Astra Zeneca Endothelin A An-tagonist 
hormone resistant 
prostate cancer 
(HRPC 
5.416 
(prostate 
cancer, ma-
lignant) 
Phase III No NA    13 11 4 9 
*Red marks: Five highest scored anticancer drugs 
